Document:

EX-10.1

Exhibit 10.1

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

DEVELOPMENT AND TOLL

MANUFACTURING AGREEMENT

between

JAVELIN PHARMACEUTICALS, INC.

and

BAXTER HEALTHCARE CORPORATION

 

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

TABLE OF CONTENTS

	 	 	 	 	 	 	 
	1.

	 	DEFINITIONS
	 	 	1	 
	2.

	 	BAXTER OBLIGATIONS FOR SUPPLY AND FUTURE DEVELOPMENT WORK	 	 	5	 
	3.

	 	API, NOVEL EXCIPIENT AND MATERIALS
	 	 	6	 
	4.

	 	MANUFACTURE
	 	 	7	 
	5.

	 	PRODUCT SPECIFICATIONS; CERTIFICATE OF ANALYSIS
	 	 	8	 
	6

	 	LABELING AND PACKAGING
	 	 	9	 
	7.

	 	FORECASTS
	 	 	9	 
	8.

	 	PURCHASE ORDERS
	 	 	9	 
	9.

	 	DELIVERY
	 	 	11	 
	10.

	 	PRICE AND PAYMENTS
	 	 	11	 
	11.

	 	INSPECTION OF PRODUCT
	 	 	12	 
	12.

	 	ACCESS TO MANUFACTURING FACILITY AND RECORDS
	 	 	12	 
	13.

	 	REPRESENTATIONS AND WARRANTIES; DISCLAIMERS; LIMITATION OF LIABILITY
	 	 	14	 
	14.

	 	INDEMNIFICATION
	 	 	16	 
	15.

	 	RECALLS
	 	 	17	 
	16.

	 	TERM AND TERMINATION
	 	 	18	 
	17.

	 	CONFIDENTIALITY
	 	 	19	 
	18.

	 	INSURANCE
	 	 	21	 
	19.

	 	MISCELLANEOUS
	 	 	21	 
	SCHEDULE 1.9	 	 	25	 
	SCHEDULE 1.27	 	 	26	 
	SCHEDULE 1.29	 	 	27	 
	SCHEDULE 1.31	 	 	28	 
	SCHEDULE 1.31A	 	 	29	 
	SCHEDULE 2.1	 	 	30	 
	SCHEDULE 10.1	 	 	31	 

 

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

DEVELOPMENT AND TOLL MANUFACTURING AGREEMENT

          This Development and Toll Manufacturing Agreement (this “Agreement”) is entered into as of
this 30th day of July, 2008 (the “Effective Date”) by and between Javelin Pharmaceuticals, Inc., a
Delaware corporation, having its principal place of business at 125 Cambridge Park Drive,
Cambridge, MA 02140 (“Purchaser”), and Baxter Healthcare Corporation, a Delaware corporation,
having a place of business at 2 Esterbrook Lane, Cherry Hill, NJ 08003 (“Supplier”).

          WHEREAS, Supplier manufactures certain pharmaceutical products;

          WHEREAS, Purchaser intends to distribute and market finished dosage pharmaceutical products,
including, without limitation, a certain intravenous dosage product sometimes currently known as
“Diclofenac Sodium Injection (the “Product”); and

          WHEREAS, Supplier and Purchaser have entered into a Development and Toll Manufacturing
Agreement, dated April 25, 2007, (“US Agreement”) for activities related to Product to be sold in
the United States, and the parties now want to enter into an agreement for activities related to
Product to be sold in certain other European countries (as defined herein), and

          NOW, THEREFORE, in consideration of the covenants and obligations expressed herein, and
intending to be legally bound hereby, the parties agree as follows:

1.       DEFINITIONS. As used in this Agreement, the following terms shall have the following
respective meanings:

	 	1.1	 	“Acceptable Product” has the meaning assigned thereto in Section 11.1.
	 
	 	1.2	 	“Activities” has the meaning assigned thereto in Section 4.3.
	 
	 	1.3	 	“Affiliate” means any individual or entity directly or indirectly
controlling, controlled by, or under common control with a party. For purposes of this
definition, “control” means the direct or indirect ownership of at least fifty percent
(50%) of the outstanding voting securities of a party, or the right to control the
policy decisions of such party. Notwithstanding the foregoing, the term “Affiliate”
does not include subsidiaries in which a party or its Affiliates owns a majority of the
ordinary voting power to elect a majority of the board of directors, but is restricted
from electing such majority by contract or otherwise, until such time as such
restrictions are no longer in effect.

1

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	1.4	 	“Alternate Presentation” means any alternative configuration of the
Product other than in two (2) mL vials with one (1) or two (2) mL fill volumes and
packaged in either a ten (10) or twenty-five (25) unit Baxter standard vial packaging
configuration.
	 
	 	1.5	 	“Alternative Source Period” has the meaning assigned thereto in Section
8.7.
	 
	 	1.6	 	“Annual Period” means a period of twelve (12) calendar months,
beginning on (i) the date of the First Regulatory Approval in one of the Member States
for the Product manufactured at the Manufacturing. Facility, or (ii) the date of
Regulatory Approval of the Product in Germany, whichever is later, and each 12-month
period thereafter during the Term.
	 
	 	1.7	 	“API” means the active pharmaceutical ingredient diclofenac sodium
USP/Ph.Eur.
	 
	 	1.8	 	“API Specifications” means the specifications for or concerning the
manufacturing, testing, and packaging of bulk API set forth in Schedule 1.88
attached hereto, as the same may be amended from time to time upon written agreement of
the parties.
	 
	 	1.9	 	“Binding Forecast” has the meaning assigned thereto in Section 7.2.
	 
	 	1.10	 	“Calendar Year” means a period of twelve (12) calendar months,
beginning each January 1 and ending on the subsequent December 31 during the Term.
	 
	 	1.11	 	“Certificate of Analysis” has the meaning assigned thereto in Section
5.2.
	 
	 	1.12	 	“Claim” has the meaning assigned thereto in Section 14.3.
	 
	 	1.13	 	“Commercially Reasonable Efforts” means efforts and resources normally
used by a party for a compound or product owned by it or to which it has rights, which
is of similar market potential at a similar stage in its product life, taking into
account the competitiveness of the marketplace, the proprietary position of the
compound or product, the regulatory structure involved, the profitability of the
applicable product, and other relevant factors.
	 
	 	1.14	 	“Confidential Information” means all proprietary and confidential
information of a party, including, without limitation, trade secrets, technical
information, business information, sales information, customer and potential customer
lists and identities, product sales plans, license and sublicense agreements,
inventions, developments, discoveries, know-how, methods, techniques, formulae, data,
processes, and other proprietary ideas, whether or not protectable under patent,

2

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	trademark, copyright, or other legal principles, that the other party has access to
or receives, but does not include information that (a) is or becomes publicly
available through no breach of this Agreement by the receiving party; (b) was
already known to the receiving party at the time it was disclosed to the receiving
party hereunder; (c) is independently developed by employees of the receiving party
without the aid, use, or application of Confidential Information received from the
disclosing party hereunder; or (d) is received from a Third Party which is under no
obligation of confidentiality to the disclosing party.
	 
	 	1.15	 	“Directives” means the European Medicines Agency (EMEA) Directives as
the same may be amended from time to time, and rules and regulations promulgated there
under.
	 
	 	1.16	 	“EMEA” means the European Medicines Agency or any successor entity.
	 
	 	1.17	 	“Force Majeure Event” has the meaning assigned thereto in Section 19.7.
	 
	 	1.18	 	“Full Lot” means Baxter’s prevailing batch size with the same
intermediate packaging, single language product insert and labeling per lot.
	 
	 	1.19	 	“GMP” means good manufacturing practice promulgated by the MHRA or
EMEA, including, without limitation, Directive 2003/94/EC, Directive 2004/27/EC,
Directive 91/412/EEC and all applicable directives, rules and regulations, policies and
guidelines in effect at a given time.
	 
	 	1.20	 	“Indemnitee” has the meaning assigned thereto in Section 14.3.
	 
	 	1.21	 	“Indemnitor” has the meaning assigned thereto in Section 14.3.
	 
	 	1.22	 	“Manufacturing Facility’” means Supplier’s facility located at 2
Esterbrook Lane, Cherry Hill, New Jersey 08003.
	 
	 	1.23	 	“Materials” means any or all chemical substances, inactive ingredients,
excipients other than the Novel Excipient, components, labels, packaging materials, and
other consumable materials used in the manufacture of the Product; provided, however,
that the term “Materials” shall not include any equipment used in the manufacture of
the Product.
	 
	 	1.24	 	“Member States” means France, Germany, United Kingdom, Spain and Italy.
	 
	 	1.25	 	“MHRA” means the Medicines and Healthcare products Regulatory Agency,
or any successor entity.
	 
	 	1.26	 	“Novel Excipient” means hydroxypropylbetadex.

3

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	1.27	 	“Novel Excipient Specifications” means the specifications for or
concerning the manufacturing, testing, and packaging of the Novel Excipient set forth
in Schedule 1.27 attached hereto, as the same may be amended from time to time
upon written agreement of the parties.
	 
	 	1.28	 	“Product” means the pharmaceutical product currently known as
Diclofenac Sodium Injection or Dyloject® containing the API.
	 
	 	1.29	 	“Product Specifications” means the specifications for or concerning the
manufacturing, testing, and packaging of Product set forth in Schedule 1.29
attached hereto, as the same may be amended from time to time upon written agreement of
the parties.
	 
	 	1.30	 	“Proposed Response” has the meaning assigned thereto in Section 12.2.
	 
	 	1.31	 	“Quality Agreement” means the applicable agreement, dated as of the
date hereof, between Supplier and Purchaser, in the form of Schedule 1.31
attached hereto relating to the Product manufactured at the Manufacturing Facility.
	 
	 	1.32	 	“Reasonable Steps” has the meaning assigned thereto in Section 17.1.
	 
	 	1.33	 	“Recall” means any action by Purchaser and its Affiliates, or Supplier
and its Affiliates, to recover title or possession or halt distribution, prescription,
or consumption of Product sold or shipped to Third Parties. The term “Recall” also
applies to Product that would have been subject to recall if it had been shipped.
	 
	 	1.34	 	“Regulations” means the MHRA Regulations as the same maybe amended from
time to time, and rules and regulations promulgated there under.
	 
	 	1.35	 	“Regulatory Approvals” means all authorizations by the appropriate
Regulatory Authorities that are required for the manufacture (other than manufacturing
facility licenses, approvals, or authorizations), marketing, promotion, pricing, and
sale of the Product in the Member States.
	 
	 	1.36	 	“Regulatory Authority” means any national, supra-national, regional,
state, or local regulatory agency, department, bureau, commission, council, or other
governmental entity in the Member States involved in the granting of Regulatory
Approval for the Product, including, without limitation, the MHRA or EMEA.
	 
	 	1.37	 	“Rolling Forecast” has the meaning assigned thereto in Article 7.
	 
	 	1.38	 	“Seizure” means any action by the MHRA or EMEA to detain or destroy
Product or prevent the distribution, prescription, consumption, or release of Product.

4

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	1.39	 	“Technical Coordinator” has the meaning assigned thereto in Section
2.2.1 hereof.
	 
	 	1.40	 	“Term” has the meaning assigned thereto in Section 16.1.
	 
	 	1.41	 	“Third Party” means any person or entity other than Supplier,
Purchaser, and their respective Affiliates.
	 
	 	1.42	 	“Unit” means each two (2) mL vial with a one (1) or two (2) mL fill
volume.

	2.	 	BAXTER OBLIGATIONS FOR SUPPLY AND FUTURE DEVELOPMENT WORK

	 	2.1	 	Process or Development Tasks. Supplier is providing development work in
accordance with the provisions of Schedule 2.1 to the US Agreement. The parties
anticipate the development work under the US Agreement will also be used for this
Agreement. Supplier shall provide Purchaser with the Marketing Authorization
Application documentation for the Product.
	 
	 	2.2	 	Development Work and Budget. If any events occur necessitating
additional process or development work, the parties will meet and develop a schedule to
define the additional work and the additional costs. Purchaser shall make payments to
Supplier for its performance of the additional work in accordance with the budget and
payment schedule (the “Budget”) established with respect to the additional work, as
described in the Development Plan within [***] days of the later to occur of (i)
completion of the relevant portion of the additional work triggering such payment
pursuant to the Budget, to Purchaser’s reasonable satisfaction, and (ii) receipt of a
detailed invoice with respect to same.
	 
	 	2.3	 	Obligation to Supply Product. During the Term, Supplier shall
manufacture and supply Product to Purchaser, and Purchaser shall purchase Product from
Supplier, pursuant to the provisions of this Agreement.
	 
	 	2.4	 	Technical Coordinator.

	 	(a)	 	Appointment. Purchaser shall appoint an authorized
technical representative and a back-up technical representative by providing
written notice of such representatives to Supplier (each, a “Technical
Coordinator”). Purchaser may replace either of its Technical Coordinators at
any time, with or without cause, by providing written notice thereof to
Supplier.
	 
	 	(b)	 	Responsibilities of Technical Coordinators. The
Technical Coordinators shall be responsible for communications, other than
legal notices, between the parties in matters of quality, manufacturing,
project management, and

5

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	compliance with respect to the Product. The Technical Coordinators shall be
available on a regular basis for consultation during the Term regarding
Supplier’s performance under this Agreement, and compliance with applicable
Specifications, Purchaser’s quality requirements, the quality requirements
of applicable laws or Regulatory Authorities having jurisdiction over the
manufacture of Product hereunder, GMPs, and all other applicable regulatory
requirements.

	 	2.5	 	Notification. Supplier shall immediately notify Purchaser of any event
that is reasonably likely to cause a breach by Supplier of its obligations under this
Agreement or of any issue that might result in a supply interruption of any duration.
	 
	 	2.6	 	[***]
	 
	 	2.7	 	Right of First Refusal for Additional European Union Member States.
Purchaser also grants to Supplier, under similar terms and conditions listed herein,
and as may need to be modified by mutual agreement of the parties (including pricing),
the right of first refusal to produce the Product, in the current presentation or in
alternate presentations for distribution and sale in countries in Europe in additional
to the Member States.

	3.	 	API, NOVEL EXCIPIENT AND MATERIALS.

	 	3.1	 	Supply of API and Materials. Purchaser has chosen those suppliers of
API, Novel Excipient and Materials identified in Purchaser’s regulatory filing for the
Product. During the Term, Supplier shall purchase API, Novel Excipient and Materials,
from those companies included in the regulatory filing for Product, for use by Supplier
in the manufacture of Product to be supplied to Purchaser under this Agreement.
	 
	 	3.2	 	Purchaser is responsible for certifying and auditing all Product-related
suppliers. At Purchasers request, Supplier will supply Purchaser with a statement
regarding supplier compliance for common suppliers used and audited by Supplier.
Supplier makes no guarantee of continued maintenance of supplier audits on a routine
basis.
	 
	 	3.3	 	Testing of API and Novel Excipient. Supplier shall test API and Novel
Excipient, in accordance with the procedures identified in Schedules 1.8 and 1.27 to
verify that the API meets the API Specifications and that the Novel Excipient meets the
Novel Excipient Specifications.

6

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	3.4	 	Failure to Meet API Specifications or Novel Excipient Specifications.
If the API provided by the API supplier fails to meet the API Specifications, or the
Novel Excipient provided by the Novel Excipient supplier fails to meet the Novel
Excipient Specifications, Supplier agrees to notify Purchaser immediately in writing,
which notice shall state with particularity the reasons such APT fails to meet the API
Specifications or such Novel Excipient fails to meet the Novel Excipient
Specifications, and shall include copies of any documentation in support of Supplier’s
conclusion. Purchaser shall timely cooperate with Supplier in addressing the failure,
and if such failure cannot be remedied, in identifying and qualifying an alternate API
supplier or Novel Excipient supplier. Such qualification shall be at Purchaser’s
expense.
	 
	 	3.5	 	Change Controls. Purchaser shall require that suppliers-provide notice
of any proposed change to the API, Novel Excipient or Materials, including process
specifications, validation and/or controls, as well as the manufacturing and/or
packaging of the API, Novel Excipient or Materials. Supplier shall not be responsible
for any failure by any supplier to provide such notice.

	4.	 	MANUFACTURE.

	 	4.1	 	Manufacturing Facility. Supplier shall manufacture all Product supplied
to Purchaser pursuant to this Agreement at the Manufacturing Facility.
	 
	 	4.2	 	Manufacture of Product. Supplier agrees to manufacture and supply the
Product in accordance with (a) the Product Specifications, (b) the applicable
Regulatory Approvals, as the same may be amended from time to time, (c) GMP
requirements, and (d) all other applicable laws, rules, regulations and internal
specifications. Upon either Party becoming aware of any proposed changes in the
Regulatory Approvals, it shall promptly notify the other Party and shall consult with
the other party regarding the proposed changes and activities. Supplier shall not have
the right to decline to implement any change in the Regulatory Approvals.
	 
	 	4.3	 	Manufacturing Changes. The Product Specifications shall be amended as
(a) reasonably requested by Purchaser or (b) necessary to conform such Product
Specifications to the regulatory requirements necessary to obtain and maintain
Regulatory Approvals with respect to the Product in the reasonable discretion of
Purchaser. If any change in the Product Specifications, or if any change in the
Regulatory Approvals, applicable laws, rules, or regulations or sources of Materials
requires either (a) a change in the Product manufacturing process, or (b) Supplier to
conduct development, testing, or other activities (e.g., process development, stability
testing, validation of new specifications) (collectively, “Activities”) in addition to
those activities Supplier conducted or is required to

7

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	conduct in its manufacture of the Product prior to such change being requested or
required, Purchaser shall reimburse Supplier for all commercially reasonable
documented costs incurred by Supplier in connection with such change. If Supplier
requires regulatory changes to support improved process or yield improvements, then
Purchaser, in consultation with Supplier, agrees to submit such changes to the EMEA
or MHRA, as required, and Supplier shall pay for such changes. Changes implemented
to support improved process or yield improvements shall not result in interruption
in the supply or quality of the Product.
	 
	 	4.4	 	Procurement of Materials. Supplier shall timely procure and maintain
adequate inventories of all API, Novel Excipient and Materials necessary for the
production of Product. Title to all such Materials shall reside in Supplier.
	 
	 	4.5	 	Regulatory Filings. Each party shall provide the other, as applicable,
with all Regulatory Approval submissions, annual reports, and correspondence to the
EMEA or MHRA on issues reasonably related to the performance of Supplier’s obligations
as set forth in this Agreement.
	 
	 	4.6	 	Compliance with Laws and Regulations. While the Product is in its
possession or under its control, Supplier shall comply with all applicable laws,
Regulations, and directives, including EMEA or MHRA requirements, regarding the
manufacture, handling, and storage of the Product.

	5.	 	PRODUCT SPECIFICATIONS; CERTIFICATE OF ANALYSIS.

	 	5.1	 	Product Specifications and Release Testing. As of the time of delivery
by Supplier, each batch of Product shall conform to the Product Specifications.
Supplier shall perform release testing according to the testing methods set forth in
the Product Specifications, to release the Product from the Manufacturing Facility.
Purchaser shall be responsible for all additional release testing.

	 	5.2	 	Certificate of Analysis. Supplier shall provide to Purchaser a
Certificate of Analysis with each shipment of Product to Purchaser or its designated
recipient stating that the Product conforms to the Product Specifications. The
Certificate of Analysis shall be in a format agreed upon by Supplier and Purchaser, and
such Certificate of Analysis shall include the results of release testing conducted by
Supplier on the Product. Supplier shall also provide Purchaser with a copy of the
manufacturing and controls information for the applicable batch(es) delivered.
Additional copies of the manufacturing and controls documentation for the applicable
batch(es) shall be provided at Purchaser’s expense, ([***] per page).

8

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

6. LABELING AND PACKAGING.
All Product shipped and delivered by Supplier to Purchaser, under this Agreement shall be
packaged and labeled in accordance with this Agreement, the then-current packaging and labeling
specifications provided by Purchaser, and GMPs. Prior to the Effective Date, Purchaser supplied
Supplier with labeling for the Product (including the EAN number(s) for the Product). Supplier
shall print, either directly or through a Third Party, labels and other printed material to be
included as part of the Product. From time to time, Purchaser may provide Supplier with modified
labeling and upon receipt thereof, Supplier shall use its Commercially Reasonable Efforts to
incorporate such new labeling on the Product in accordance with Purchaser’s requested schedule
therefore. Purchaser shall provide Supplier with any modifications to the labeling for the Product
as promptly as possible in order to ensure compliance with any and all applicable regulations.
Purchaser shall reimburse Supplier for all pre-approved commercially reasonable costs incurred by
Supplier in making modifications to labeling, branding, or imprinting packaging and/or
manufacturing processes to accommodate Purchaser’s new labeling or to accommodate any other changes
requested by Purchaser and agreed to by Supplier. Such reimbursement shall be made pursuant to
invoices submitted by Supplier to Purchaser, which invoices shall be payable within [***] days
after Purchaser’s receipt thereof Upon Purchaser’s request, Supplier shall promptly enter into a
separate written label agreement with Purchaser, setting forth Supplier’s obligations relating to
the labeling of Product hereunder.

7. FORECASTS. Throughout the Term, Purchaser, shall provide Supplier with a rolling one (1)
year forecast by calendar month (the “Rolling Forecast”) of its expected purchases of Product as
follows:

	 	7.1	 	Forecasts. On or before each [***] during the Term, Purchaser shall
provide Supplier with a written forecast of Purchaser’s expected purchases of Product
for a period of [***] calendar months beginning on the date of such forecast. [***]
percent of the forecast for the [***] calendar months and [***] percent of the forecast
for the [***] calendar months shall be binding on Purchaser, subject to Section 8.3,
and the forecast for the [***] calendar months shall not be binding on Purchaser. As
soon as commercially reasonable, Purchaser shall supply an initial forecast.
	 
	 	7.2	 	Binding Forecasts. The portion of each Rolling Forecast that is binding
on Purchaser as provided in Section 7.1 shall be a “Binding Forecast.” The portion of
each Rolling Forecast that is not binding on Purchaser as provided in Section 7.1 shall
be used by Supplier and Purchaser solely for planning purposes.

	8.	 	PURCHASE ORDERS.

	 	8.1	 	Placement of Purchase Orders. From time to time during the Term,
Purchaser shall place purchase orders with Supplier, in a format chosen by Purchaser,

9

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	specifying the quantity of Product desired in Full Lots, and the place(s) to which
and the manner and dates by which delivery is to be made; said delivery dates to be
no earlier than [***] calendar days after the purchase order date. All purchase
orders shall be sent by Purchaser to the following address or via electronic
exchange:

Baxter Healthcare Corporation

2 Esterbrook Lane

Chevy Hill, New Jersey 08003

Attn.: Director of Logistics

Tel.: 856-489-2114

Fax: 856-424-2592

	 	 	 	 or to such other addresses as Supplier may notify Purchaser from time to time.
	 
	 	8.2	 	Acceptance of Purchase Orders. Purchase orders made in accordance with
this Article 8 shall be deemed to be accepted by Supplier if Supplier has not rejected
said purchase orders within [***] business days after receipt of the same; provided,
however, that Supplier shall not reject any purchase order specifying quantities which
purchase orders are otherwise in accordance with the provisions of this Article 8.
	 
	 	8.3	 	Quantity Limitations. Supplier shall execute all accepted purchase
orders for quantities of Product ordered up to and including [***] percent of the
quantity of Product set forth in the applicable Binding Forecast for each calendar
month. Supplier shall use its Commercially Reasonable Efforts to fulfill orders for
quantities of Product greater than [***] percent of the quantity set forth in the
applicable Binding Forecast for each calendar month.
	 
	 	8.4	 	Minimum Purchase Requirements. Following receipt of Regulatory Approval
for the Product, Purchaser shall purchase a Minimum of [***] Units in the first Annual
Period and [***] Units during each Annual Period thereafter. In any Annual Period in
which Purchaser does not purchase the Minimum Units, Purchaser shall pay to Supplier
[***].
	 
	 	8.5	 	Conflict. In the event of any conflict between the provisions of this
Agreement and any purchase order, the provisions of this Agreement shall control.
	 
	 	8.6	 	Failure to Supply. In the event (i) Supplier cannot or does not
properly satisfy all of Purchaser’s Orders for Product on a timely basis in accordance
with this Section 8 for a period of [***] days, and such failure is not attributable to
a failure to properly supply API, Novel Excipient or Materials by the suppliers, or
(ii) any facility involved in the manufacture or storage of Product hereunder is
prohibited

10

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	from, or materially adversely affected in its ability to, produce, store, or
otherwise
be involved in the provision of Product to Purchaser under this Agreement by the
appropriate regulatory authorities, and such material adverse event is not a Force
Majeure Event, Purchaser can qualify an alternate manufacturing source and purchase
Product from such alternate source until such time as Supplier can resume
manufacture of the Products (the “Alternate Source Period”). Supplier shall, as
requested by Purchaser and at Supplier’s expense, provide the technical transfer
package for the Product to Purchaser and/or third parties designated by Purchaser to
manufacture Product in accordance with all legal and regulatory requirements as
quickly as possible. [***].

9. DELIVERY. Supplier shall execute all accepted purchase orders by delivering the
appropriate quantity of Product to Supplier’s designated mutually agreeable carrier(s) at the
Manufacturing Facility no later than the delivery dates provided in the applicable purchase order.
Title and risk of loss shall pass to Purchaser when each order of Product is delivered to the
designated carrier at the Manufacturing Facility. Supplier shall instruct the designated carrier to
deliver the Product to such address as Purchaser may provide to Supplier from time to time. All
shipments shall be accompanied by temperature monitoring devices or other indicators, at
Purchaser’s expense.

	10.	 	PRICE AND PAYMENTS.

	 	10.1	 	Price. Purchaser shall purchase from Supplier, and Supplier shall sell
to Purchaser, Product at the purchase price set forth in Schedule 10.1 attached. The
pricing may be adjusted [***], beginning on [***] and [***] thereafter during the
Initial Term, as defined in Section 16. 1, and any renewals, by a percentage equal to
the percentage change in the [***] during the [***]-month period ending the preceding
[***] (or if discontinued such equivalent index as is mutually agreed to by the
parties). [***].
	 
	 	10.2	 	Freight, Insurance, and Taxes. Purchaser shall pay all actual freight,
insurance, and government sales tax imposed on purchasers for resale, and duties and
other fees (except tax on income to Supplier) incurred in connection with the sale and
shipment of Product to Purchaser.
	 
	 	10.3	 	Payment. Payments to Supplier for the purchase price of Product, as
well as any other payment due from Purchaser to Supplier pursuant to this Agreement,
shall be made by Purchaser within [***] days after the later of the date of invoice or
the product ship date from the Manufacturing Facility, except as to orders for Product
that are rejected by Purchaser in accordance with the procedures set forth in Article
11 or that the parties dispute are in conformance with the Specifications. In the event
that Product is rejected by Purchaser, but is determined to be Acceptable Product
pursuant to Section 11.2, the payment for such Product shall

11

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	be due and payable within [***] business days after the determination with respect
to such Product is made in accordance with Section 11.2 hereof.

	11.	 	INSPECTION OF PRODUCT.

	 	11.1	 	Inspection, Rejection of Product. Purchaser may analyze representative
samples of each lot of Product delivered hereunder for purposes of determining whether
the same meets the Specifications and was manufactured in accordance with GMP
(“Acceptable Product”), and, if performed, shall do so within [***] days from the date
of shipment (or, in the case of a latent defect, within [***] days after discovery of
such latent defect). Purchaser shall notify Supplier in writing within said [***] days
of rejection of any of the Product that Purchaser is rejecting said Product because it
is not Acceptable Product.
	 
	 	11.2	 	Third Party Analysis. If Supplier, after good faith consultation with
Purchaser, disputes any finding by Purchaser that Product is not Acceptable Product,
representative samples of such Product shall be forwarded to a Third Party jointly
selected by Supplier and Purchaser for analysis, which analysis shall be performed in
compliance with applicable MHRA Regulations for retesting of pharmaceutical products.
The findings of such Third Party regarding whether the Product was Acceptable Product
shall be binding upon Supplier and Purchaser. The cost of such analysis by such Third
Party shall be borne by the party whose findings differed from those generated by such
Third Party.
	 
	 	11.3	 	Replacement of Product. Unless any nonconformity is caused by a
negligent or wrongful act or omission by Purchaser or its agents, Supplier shall, at no
cost to Purchaser, and at Purchaser’s election: (a) replace any Product order, or
portion thereof, that is not Acceptable Product within [***] days; or (b) cancel any
order or portion of an order for which non-Acceptable Product was delivered.
	 
	 	11.4	 	Disposition of Rejected Product. Supplier shall instruct Purchaser as
to the disposition of any Product order or portion thereof determined not to be
Acceptable Product. At the sole option of Supplier, said Product may be returned to
Supplier, at Supplier’s expense, including shipping costs, or destroyed in an
environmentally acceptable manner, at Supplier’s expense.
	 
	 	11.5	 	Qualified Persons Requirements. The costs of services or audits
provided by an EMEA Qualified Person(s) will be borne by Purchaser.

	12.	 	ACCESS TO MANUFACTURING FACILITY AND RECORDS.

	 	12.1	 	Inspection b Regulatory Authorities. Upon the request of the MHRA, EMEA
or other Regulatory Authority, such Regulatory Authority shall have access to

12

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	observe and inspect the Manufacturing Facility and procedures used for the
manufacture, testing, labeling, packaging and/or warehousing of the Product and to
audit such facilities for compliance with GMP and/or other applicable regulatory
standards.
	 
	 	12.2	 	Notification of Injuries and Inspections. Supplier shall notify
Purchaser within two (2) business days of any written or oral inquiries, notifications,
observations or inspection activity by the MHRA, EMEA or other Regulatory Authority in
regard to any Product. Supplier shall provide a complete description of any such
governmental inquiries, notifications, inspections or observations promptly after such
visit or inquiry. Supplier shall furnish to Purchaser (a) within two (2) business days
after receipt, any report or correspondence issued by the MHRA, EMEA or other
Regulatory Authority in connection with such visit or inquiry, including, but not
limited to, any EMEA or MHRA observations, that pertain to the Product in the Member
States, and (b) not later than five (5) business days prior to the time it provides to
the MHRA, EMEA or other Regulatory Authority, copies of proposed responses or
explanations relating to items set forth above (each, a “Proposed Response”), in each
case redacted of trade secrets or other confidential or proprietary information of
Supplier that are unrelated to its obligations under this Agreement or to Product.
Supplier shall discuss with Purchaser and consider in good faith any comments provided
by Purchaser on the Proposed Response. After the filing of a response with the
Regulatory Authority, Supplier shall notify Purchaser and provide Purchaser with copies
of any further contacts with such agency relating to the subject matter of the
response.
	 
	 	12.3	 	Inspection by Purchaser. Supplier shall permit Purchaser or
Purchaser’s mutually agreed upon designee to inspect once annually that portion of the
Manufacturing Facility where Product is manufactured (including those sections of the
manufacturing, packaging, laboratory and warehousing facilities utilized in the
manufacture, packaging, storage, testing, shipping or receiving of Products. Such
inspections may include Active Ingredients, the work in process and Products as well as
all batch records). Such right shall also include the right to review such documents as
is reasonably necessary for the purpose of assessing Supplier’s compliance with the
Product Specifications and applicable regulations. Such inspection and document review
shall be conducted upon reasonable prior notice by Purchaser, but not less than thirty
(30) days prior to the proposed inspection, at a time and date mutually agreeable to
Supplier and Purchaser, and shall be coordinated by the Technical Coordinators.
Purchaser shall also have a right to inspect the Manufacturing Facility as set forth in
this Section 12.3 at any time during the Term if (i) Purchaser has reasonable cause to
be concerned with whether the Manufacturing Facility complies with applicable
regulations, or (ii) in the event an audit results in adverse findings in which case
Purchaser shall be

13

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	entitled to re-audit the Manufacturing Facility, until the adverse findings are
resolved, without reference to the once annual limitation.

	13.	 	REPRESENTATIONS AND WARRANTIES; DISCLAIMERS; LIMITATION OF LIABILITY.

	 	13.1	 	Representations and Warranties by Supplier. Supplier hereby represents,
warrants and covenants that:

	 	(a)	 	it is a corporation or entity duly organized and validly
existing under the laws of the state of its incorporation;
	 
	 	(b)	 	the execution, delivery, and performance of this Agreement by
Supplier has been duly authorized by all requisite corporate action and does
not require any shareholder action or approval,
	 
	 	(c)	 	it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder;
	 
	 	(d)	 	the execution, delivery, and performance by Supplier of this
Agreement and its compliance with the provisions of this Agreement does not and
shall not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) any other Agreement to which it
is a party; (ii) the provisions of its charter or operative documents or
bylaws; or (iii) any order, writ, injunction, or decree of any court or
governmental authority entered against it or by which any of its property is
bound;
	 
	 	(e)	 	it shall at all times comply with all applicable material laws
and regulations relating to its activities under this Agreement;
	 
	 	(f)	 	all Product supplied hereunder conforms to the Product
Specifications and any manufacturing, packaging, labeling or storage
specifications provided by Purchaser to Supplier, has been and shall be
manufactured, packaged, labeled and stored in accordance with the applicable
Regulatory Approvals and GMP, and was not adulterated or misbranded while in
Supplier’s possession or at any time prior to delivery of such Product by
Supplier hereunder.

	 	13.2	 	Representations and Warranties by Purchaser. Purchaser hereby
represents, warrants and covenants that:

14

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	(a)	 	it is a corporation or entity duly organized and validly
existing under the laws of the state of its incorporation;
	 
	 	(b)	 	the execution, delivery, and performance of this Agreement by
Purchaser has been duly authorized by all requisite corporate action and does
not require any shareholder action or approval;
	 
	 	(c)	 	it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder;
	 
	 	(d)	 	the execution, delivery, and performance by Purchaser of this
Agreement and its compliance with the provisions of this Agreement does not and
shall not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) any other Agreement to which it
is a party; (ii) the provisions of its charter or operative documents or
bylaws; or (iii) any order, writ, injunction, or decree of any court or
governmental authority entered against it or by which any of its property is
bound; and
	 
	 	(e)	 	it shall at all times comply with all applicable material laws
and regulations relating to its activities under this Agreement.

	 	13.3	 	Disclaimer of Warranties by Supplier. EXCEPT AS EXPRESSLY SET FORTH IN
THIS AGREEMENT, SUPPLIER HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED, OR
STATUTORY, WITHRESPECT TO THE PRODUCT AND THE MANUFACTURING FACILITY, INCLUDING, BUT
NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, TITLE, AND NON-INFRINGEMENT.
	 
	 	13.4	 	Disclaimer of Warranties by Purchaser. EXCEPT AS EXPRESSLY SET FORTH IN
THIS AGREEMENT, PURCHASER EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED, OR
STATUTORY, WITH RESPECT TO THE API OR PRODUCT, INCLUDING, BUT NOT LIMITED TO, ANY
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND
NONINFRINGEMENT.
	 
	 	13.5	 	Limitation of Liability. EXCEPT IN CONNECTION WITH A BREACH BY EITHER
PARTY OF ARTICLE 17, THE INDEMNIFICATION OBLIGATION OF SUPPLIER UNDER SECTION 14.1, AND
THE INDEMNIFICATION OBLIGATION OF PURCHASER UNDER SECTION 14.2, NEITHER SUPPLIER NOR
PURCHASER SHALL BE LIABLE FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY, OR
INCIDENTAL

15

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF REVENUE, LOSS OF PROFITS, COST OF
REPLACEMENT, OR COMMERCIAL LOSS) ARISING OUT OF OR RELATED TO THIS AGREEMENT,
HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY (INCLUDING, WITHOUT LIMITATION,
NEGLIGENCE), EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

	14.	 	INDEMNIFICATION.

	 	14.1	 	Indemnification by Supplier. Supplier shall indemnify and hold harmless
Purchaser, its Affiliates, and its and their officers, directors, employees, and agents
from and against any and all losses, claims, damages, liabilities, obligations,
penalties, judgments, awards, costs, expenses, and disbursements, including, without
limitation, the costs, expenses, and disbursements, as and when incurred, of
investigating, preparing, or defending any action, suit, proceeding, or investigation
asserted by a Third Party (including, without limitation, reasonable attorneys’ fees
and expenses), caused by, relating to, based upon, arising out of, or in connection
with (a) any failure of Product supplied hereunder to conform to the Product
Specifications; (b) any failure of Product supplied hereunder to be manufactured in
accordance with applicable Regulatory Approvals and GMP; (c) any adulteration of
Product supplied hereunder while in Supplier’s possession; (d) breach of any of
Supplier’s representations, warranties, or covenants under this Agreement; or (e)
Supplier’s willful misconduct or negligence.
	 
	 	14.2	 	Indemnification by Purchaser. Purchaser shall indemnify and hold
harmless Supplier and its officers, directors, employees, and agents from and against
any and all losses, claims, damages, liabilities, obligations, penalties, judgments,
awards, costs, expenses, and disbursements, including, without limitation, the costs,
expenses, and disbursements, as and when incurred, of investigating, preparing, or
defending any action, suit, proceeding, or investigation asserted by a Third Party
(including, without limitation, reasonable attorneys’ fees and expenses), caused by,
relating to, based upon, arising out of, or in connection with (a) breach of any of
Purchaser’s representations, warranties, or covenants under this Agreement; or (b)
Purchaser’s willful misconduct or negligence.
	 
	 	14.3	 	Procedure for Indemnification. Each party seeking to be reimbursed,
indemnified, defended, and/or held harmless under Sections 14.1 or 14.2 (each, an
“Indemnitee”) shall (a) provide the party obligated to indemnify such Indemnitee (the
“Indemnitor”) with prompt, written notice of any claim, suit, demand, or other action
for which such Indemnitee seeks to be reimbursed, indemnified, defended, and/or held
harmless (each, a “Claim”), which notice shall include a reasonable identification of
the alleged facts giving rise to such Claim; (b) grant such party reasonable authority
and control over the defense and settlement of any

16

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	such Claim; and (c) reasonably cooperate with such party and its agents in defense
of any such Claim, at the Indemnitor’s expense. Each Indemnitee shall have the right
to participate in the defense of any Claim for which Indemnitee seeks to be
reimbursed, indemnified, defended, or held harmless, by using attorneys of such
Indemnitee’s choice, at such Indemnitee’s expense. Any settlement of a Claim for
which any Indemnitee seeks to be reimbursed, indemnified, defended, and/or held
harmless under this Article 14 shall be subject to the prior written approval of
such Indemnitee, which approval shall not be unreasonably withheld, conditioned, or
delayed.

	15.	 	RECALLS.

	 	15.1	 	Recall. In the event of an actual or threatened Recall of API or
Product required or recommended by a Regulatory Authority of competent jurisdiction
within the Member States, or if Recall of API or Product is reasonably deemed advisable
by Purchaser in its sole discretion, such Recall shall be promptly implemented and
administered by Purchaser in a manner which is appropriate and reasonable under the
circumstances and in conformity with accepted trade practices. Supplier shall assist
Purchaser as requested by Purchaser to ensure a timely, accurate, and complete Recall.
The costs of any such Recall shall be borne by the party or parties whose actions or
omissions caused the Recall to be necessary. Supplier shall have no obligation to pay
costs of Recalls of API. Supplier shall have no obligation to pay costs of Recalls of
Product to the extent such recalls are (a) caused by actions of Third Parties occurring
after such Product is sold by Purchaser; (b) due to design defects in the
specifications, packaging or labeling not attributable to Supplier’s execution of its
responsibilities under this Agreement; or (c) due to any other breach by Purchaser of
its duties under this Agreement, unless such Recall is due to a breach by both
Purchaser and Supplier of their duties under this Agreement.
	 
	 	15.2	 	Duty to Inform. Each party shall keep the other party fully and
promptly informed of any notification, event, or other information, whether received
directly or indirectly, which might affect the marketability, safety, or effectiveness
of Product or might result in a Recall or Seizure of API or Product by the MHRA, EMEA
or other Regulatory Authority.
	 
	 	15.3	 	Recall Due to Supplier Breach. In the event of any Recall or Seizure
arising out of or resulting from Supplier’s breach of this Agreement, Supplier shall,
at the election of Purchaser, either:

	 	(a)	 	supply Product, without charge to Purchaser, in an amount
sufficient to replace the amount of Product Recalled or Seized; or

17

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	(b)	 	refund to Purchaser, or give credit to Purchaser against
outstanding receivables due from Purchaser, against the price of Product to be
delivered to Purchaser in the future, in amounts equal to the price paid by
Purchaser to Supplier for Product so Recalled or Seized plus the reasonable
transportation costs incurred by Purchaser and not otherwise recovered by
Purchaser in respect of such Recalled or Seized Product.

	 	 	 	Supplier shall also pay to Purchaser Purchaser’s reasonable out-of-pocket expenses
incurred in connection with such Recall or Seizure.
	 
	 	15.4	 	Recall Not Due to Supplier Breach. In the event of any Recall or
Seizure not arising out of or resulting from Supplier’s breach of this Agreement,
Purchaser shall pay to Supplier Supplier’s reasonable out-of-pocket expenses incurred
in connection with such Recall or Seizure.

	16.	 	TERM AND TERMINATION.

	 	16.1	 	Term and Renewal. This Agreement shall begin on the Effective Date and
shall continue for three (3) years from the date of the first Regulatory Approval in a
Member State for Product manufactured at the Manufacturing Facility (the “Initial
Term”). There after, the Agreement will be automatically extended for consecutive [***]
year terms unless either party notifies the other party in writing [***] months in
advance of its desire not to extend the Agreement.
	 
	 	16.2	 	Termination for Breach. Either party may terminate this Agreement
immediately by giving notice to the other party in the event that the other party
commits a breach of any material provision of this Agreement that is not cured within
[***] days after notice thereof by the non-breaching party.
	 
	 	16.3	 	Termination for Insolvency. Either party may terminate this Agreement
immediately in the event that the other party becomes the subject of a voluntary or
involuntary proceeding relating to insolvency, receivership, liquidation, or
composition for the benefit of creditors.
	 
	 	16.4	 	Termination for Failure to Acquire MHRA or EMEA Approval. Either party
may terminate this Agreement if the MHRA or EMEA has not approved the Product as
manufactured in the Manufacturing Facility by [***]. However, prior to exercising this
termination right, if the Product is still under review by the MHRA or EMEA on [***],
the parties will negotiate in good faith to continue the Agreement.
	 
	 	16.5	 	Upon Expiration or Termination.

18

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	16.5.1	 	Confidential Information. Upon expiration or termination of this
Agreement, all Confidential Information shall be returned to the disclosing
party or destroyed unless otherwise specified or permitted elsewhere under this
Agreement. The parties may retain one (1) copy of Confidential Information for
archival purposes only.
	 
	 	16.5.2	 	Materials. Upon expiration or termination of this Agreement, Supplier
shall deliver all Materials purchased by Supplier in anticipation of
manufacture of Product hereunder in accordance with the Rolling Forecasts, at
Purchaser’s expense. Supplier shall submit an invoice to Purchaser for the
reasonable cost of such Materials, and Purchaser shall pay such invoice within
[***] days after the invoice date.
	 
	 	16.5.3	 	Survival. The following provisions shall survive termination or
expiration of this Agreement: Articles 13-15, this Section 16.5.3, Articles
17-19, any payment obligations of the parties accruing hereunder prior to the
expiration or termination of this Agreement, and any other provision that is
necessary to interpret the respective rights and obligations of the parties
hereunder.

	 	16.6	 	Termination at Will. Following the start of the first Annual Period,
Purchaser shall have the right to terminate this Agreement at any time during the Term
for any reason by giving Supplier no less than twenty-four (24) months prior written
Notice.

	17.	 	CONFIDENTIALITY.

	 	17.1	 	Confidentiality Obligations. Except as permitted elsewhere under this
Agreement, during the Term and thereafter until the third (3rd) anniversary of the
effective date of termination or expiration of this Agreement, each party agrees to
take Reasonable Steps (as defined in this Section 17.1) (a) to receive and maintain the
Confidential Information of the other party in confidence, (b) not to disclose such
Confidential Information to any third party, and (c) to promptly notify the disclosing
party upon learning of any law, rule, regulation, or court order that purports to
compel disclosure of any Confidential Information of the disclosing party and to
reasonably cooperate with the disclosing party, at the disclosing party’s expense, in
the exercise of the disclosing party’s right to protect the confidentiality of such
Confidential Information. Neither party hereto shall use all or any part of the
Confidential Information of the other party for any purpose other than to perform its
obligations under this Agreement. The parties shall take Reasonable Steps (as defined
in this Section 17.1) to ensure that their employees, representatives, and agents
comply with this provision, and shall be responsible for any breach by such employees,
representatives, and agents. As used herein,

19

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	“Reasonable Steps” means at least the same degree of care that the receiving party
uses to protect its own Confidential Information, and in, no event, no less than
reasonable care.
	 
	 	17.2	 	Exclusions. Nothing contained herein shall prevent a party from
disclosing Confidential Information pursuant to any applicable law, rule, regulation,
or court order; provided, however, that such party complies with the notice provisions
of Section 17.1(c) to the extent permissible under applicable laws, rules, regulations,
or court orders. Such disclosure shall not alter the status of such information
hereunder for all other purposes as Confidential Information. In addition, nothing
contained herein shall prevent a party from disclosing Confidential Information that:

	 	(a)	 	is generally known to the public at the time of disclosure or
becomes generally known through no wrongful act on the part of the Recipient;
	 
	 	(b)	 	can be shown by writing to have been in the Recipient’s
possession at the time of disclosure otherwise than as a result of any prior
confidential disclosure by the Disclosing Party or another party or the
Recipient’s breach of any legal obligation;
	 
	 	(c)	 	becomes known to the Recipient through disclosure by sources
other than the Disclosing Party having no duty of confidentiality with respect
to such Confidential Information, whether to the Disclosing Party or another
party, and having the legal right to disclose such Confidential Information; or
	 
	 	(d)	 	is independently developed by the Recipient without reference
to or reliance upon the Confidential Information.

	 	17.3	 	Remedies. Each party acknowledges and agrees that the provisions of
this Article 17 are reasonable and necessary to protect the other party’s interests in
its Confidential Information, that any breach of the provisions of this Article 17 may
result in irreparable harm to such other party, and that the remedy at law for such
breach may be inadequate. Accordingly, in the event of any breach or threatened breach
of the provisions of this Article 17 by a party hereto, the other party, in addition to
any other relief available to it under this Agreement, at law, in equity, or otherwise,
shall be entitled to seek temporary and permanent injunctive relief restraining the
breaching party from engaging in and/or continuing any conduct that would constitute a
breach of this Article 17, without the necessity of proving actual damages or posting a
bond or other security.

20

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	18.	 	INSURANCE.

	 	18.1	 	Each party shall obtain and keep in force during the term of this Agreement,
general comprehensive liability insurance and product liability insurance covering
occurrence of bodily injury and property damage in an amount of not less than $[***]
combined single limit; provided, however, that Supplier may self-insure for this type
of coverage.
	 
	 	18.2	 	Each party shall carry the insurance coverage set forth herein during the term
of this Agreement and through the later of [***] years following termination of this
Agreement or [***] following the expiration of the last to expire Product made in
accordance with this Agreement. Each party shall have the right to request from the
other party certificates of insurance and shall require at least thirty (30) days
written notice to such party prior to any cancellation, nonrenewal or reduction in
coverage below the minimum pursuant to Section 18.1.

	19.	 	MISCELLANEOUS

	 	19.1	 	Assignment. During the term of this Agreement the rights of either
party under this Agreement shall not be assigned, nor shall the performance of either
party’s duties be delegated without the other party’s prior written consent, such
consent to not be unreasonably withheld, except either party may assign this agreement
to an Affiliate, a purchaser or o licensee of all or substantially all of such party’s
business related to the sales of the Product in the Member States. Notice of assignment
shall be given to other party at least thirty (30) days prior to the effective date of
said assignment.
	 
	 	19.2	 	Entire Agreement. This Agreement, together with the referenced
schedules, embodies and shall constitute the entire agreement and understanding of the
parties relating to the subject matter of this Agreement and shall supersede all prior
oral or written agreements, contracts, understandings, representations, or
arrangements, whether oral or written, between them, relating to the subject matter of
this Agreement.
	 
	 	19.3	 	Modification. No change or addition may be made to this Agreement or
any schedule attached hereto except in writing, signed by a duly authorized
representative of each party, and expressly stating that it is a modification of this
Agreement.
	 
	 	19.4	 	Notices. All communications between the parties with respect to any of
the provisions of this Agreement shall be sent to the addresses set forth below, or to
such other addresses as designated by one party to the other party by notice pursuant
to this Section 19.4, by nationally recognized courier or by prepaid certified mail, or
by facsimile transmission or other electronic means of communications, with
confirmation by letter given by the close of business on or

21

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	before the next following business day. All notices provided hereunder shall be
effective upon receipt.
	 
	 	 	 	If to Purchaser, to:

Javelin Pharmaceuticals, Inc.

125 Cambridge Park Drive

Cambridge, MA 02140

Attn: VP - Clinical & Commercial Manufacturing

Tel.: 212-554-4362

Fax: 212-554-4554

with a copy, which copy shall not constitute notice, to:

Javelin Pharmaceuticals, Inc.

125 Cambridge Park Drive

Cambridge, MA 02140

Attn: General Counsel

Tel.: 617-349-4512

Fax: 617-349-4505

If to Supplier, to:

Baxter Healthcare Corporation

2 Esterbrook Lane

Cherry Hill, New Jersey 08003-4099

Attn.: Plant Manager

Tel.: 856-489-2189

Fax: 856-424-8747

with a copy, which copy shall not constitute notice, to:

Baxter Healthcare Corporation

One Baxter Parkway

Deerfield, IL 60015

Attn.: General Counsel

Tel.: 847-948-2600

Fax: 847-948-2450

	 	19.5	 	Severability. If any provision of this Agreement is held to be void or
unenforceable by a court of competent jurisdiction, such finding(s) shall not be
construed to render any other provision of this Agreement either void or

22

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	unenforceable, and all other provisions shall remain in full force and effect. Upon
any such determination, the parties shall make such amendments to this Agreement as
necessary to remove the invalid or unenforceable part of any such provision, but
otherwise achieve to the maximum extent permissible, the economic, legal, and
commercial intent and objectives of the original provision.
	 
	 	19.6	 	Waiver. Failure or delay by either party in exercising or enforcing any
provision, right, or remedy under this Agreement, or waiver of any remedy hereunder, in
whole or in part, shall not be deemed a waiver thereof, or prevent the subsequent
exercise of that or any other rights or remedy.
	 
	 	19.7	 	Force Majeure. Neither Purchaser nor Supplier shall be in breach of
this Agreement if there is any failure of performance under this Agreement occasioned
by any act of God, fire, act of government or state, war, civil commotion,
insurrection, embargo, prevention from or hindrance in obtaining energy or other
utilities, labor disputes of whatever nature, failure by a supplier to supply API,
Novel Excipient or Materials or any other reason beyond the control and without the
fault or negligence of the party affected thereby (a “Force Majeure Event”). Such
excuse shall continue as long as the Force Majeure Event continues. Upon cessation of
such Force Majeure Event, the affected party shall promptly resume performance
hereunder. Each party agrees to give the other party prompt written notice of the
occurrence of any Force Majeure Event, the nature thereof, and the extent to which the
affected party will be unable fully to perform its obligations hereunder. Each party
further agrees to use reasonable efforts to correct the Force Majeure Event as quickly
as possible and to give the other party prompt written notice when it is again fully
able to perform such obligations. In the event any Force Majeure event prevents
Supplier from supplying Product for a period longer than one hundred twenty (120) days,
Purchaser shall have the right to source the Product from Third Parties or to appoint
another supplier of the Product.
	 
	 	19.8	 	Headings. The headings and captions used in this Agreement are solely
for the convenience of reference and shall not affect its interpretation.
	 
	 	19.9	 	Independent Contractors. The parties acknowledge, agree and declare
that the relationship hereby established between them is solely that of provider and
recipient of manufacturing services and that each party hereto is an independent
contractor with respect to the other.
	 
	 	19.10	 	Maintenance of Agreement. Supplier shall keep a copy of this Agreement
and any amendments hereto at the Manufacturing Facility, and at any other location
permitted in accordance with this Agreement where the Product is packaged or labeled,
during the Term and for a period of two (2) years following the date of

23

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	the final shipment of Product from such facility or location. Supplier shall make
such copy of the Agreement and any amendments hereto available for inspection at any
reasonable hour to any officer or employee of the MHRA or EMEA who requests such
copy in the course of performing his or her duties for the MHRA or EMEA
	 
	 	19.11	 	Choice of Law, Jurisdiction. The provisions of this Agreement shall be
governed by and construed in accordance with the laws of the State of Delaware, without
regard to conflict of laws principles. Any and all disputes between the parties arising
out of or related to this Agreement shall be heard in the state and federal courts
located in the State of Delaware, and the parties hereby consent and submit to the
jurisdiction of such courts.
	 
	 	19.12	 	Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall constitute together the same document.

          IN WITNESS WHEREOF, the parties hereto, by their authorized officers, have executed this
Agreement as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	JAVELIN PHARMACEUTICALS, INC.	 	 	 	BAXTER HEALTHCARE CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Martin Driscoll
	 	 	 	By:
	 	/s/ Peter J. Arduini	 	 
	 

	 	Name: Martin Driscoll
	 	 	 	 	 	Name: Peter J. Arduini	 	 
	 

	 	Title: Chief Executive Officer
	 	 	 	 	 	Title: Corporate Vice President and
	 	 
	 

	 	 	 	 	 	 	 	         President, Medication Delivery	 	 

24

 

 [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.9

API SPECIFICATIONS

See attached specifications.

To be added by the parties upon filing of the Marketing Authorization Application with the
Regulatory Authorities.

25

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.27

NOVEL EXCIPIENT SPECIFICATIONS

See attached specifications.

To be added by the parties upon filing of the Marketing Authorization Application with the
Regulatory Authorities.

26

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.29

PRODUCT SPECIFICATIONS

[***]

27

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.31

QUALITY (TECHNICAL) AGREEMENT

[***]

28

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.31A

LIST OF CONTACTS

[***]

29

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 2.1

PACKAGING DEVELOPMENT

30

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 10.1

PRICING

[***]

31EX-10.1

Exhibit 10.1

The following Security Agreement
has been filed to provide investors with information regarding its terms. It is not intended
to provide any other factual information about Martha Stewart Living Omnimedia. The
representations and warranties of the parties in this Security Agreement were made to, and
solely for the benefit of, the other parties. The assertions embodied in the representations
and warranties are qualified by information included in disclosure schedules exchanged by the
parties that may modify or create exceptions to the representations and warranties. Accordingly,
investors should not rely on the representations and warranties as characterizations of the actual
state of facts at the time they were made or otherwise.

 

 

 

SECURITY AGREEMENT

dated as of

July 31, 2008

among

MARTHA STEWART LIVING OMNIMEDIA, INC.,

MSLO EMERIL ACQUISITION SUB LLC,

as Grantors

and

BANK OF AMERICA, N.A.,

as Collateral Agent

 

 

 

Table of Contents

	 	 	 	 	 
	 	 	 Page
	ARTICLE I DEFINITIONS
	 	 	1	 
	SECTION 1.01 Loan Agreement
	 	 	1	 
	SECTION 1.02 Other Defined Terms
	 	 	1	 
	ARTICLE II SECURITY INTERESTS
	 	 	5	 
	SECTION 2.01 Security Interest
	 	 	5	 
	ARTICLE III REPRESENTATIONS WARRANTIES AND COVENANTS
	 	 	8	 
	SECTION 3.01 General Representations and Warranties
	 	 	8	 
	SECTION 3.02 Covenants
	 	 	9	 
	SECTION 3.03 Other Actions
	 	 	11	 
	ARTICLE IV CERTAIN PROVISIONS CONCERNING INTELLECTUAL PROPERTY
	 	 	13	 
	SECTION 4.01 Representations and Warranties
	 	 	13	 
	SECTION 4.02 Grant of License
	 	 	13	 
	SECTION 4.03 Protection of Collateral Agent’s Security
	 	 	14	 
	SECTION 4.04 Modifications
	 	 	14	 
	SECTION 4.05 Litigation
	 	 	15	 
	SECTION 4.06 Intellectual Property Security Agreements
	 	 	15	 
	SECTION 4.07 After-Acquired Property
	 	 	15	 
	SECTION 4.08 Assignments
	 	 	16	 
	SECTION 4.09 Power of Attorney
	 	 	16	 
	ARTICLE V CERTAIN PROVISIONS CONCERNING PLEDGED COLLATERAL
	 	 	17	 
	SECTION 5.01 Representations and Warranties
	 	 	17	 
	SECTION 5.02 Delivery of the Pledged Collateral
	 	 	18	 
	SECTION 5.03 Certification of Limited Liability Company and Limited Partnership Interests
	 	 	18	 
	SECTION 5.04 Registration in Nominee Name; Denominations
	 	 	18	 
	SECTION 5.05 Voting Rights; Dividends and Interest
	 	 	18	 
	ARTICLE VI REMEDIES
	 	 	20	 
	SECTION 6.01 Remedies Upon Default
	 	 	20	 
	SECTION 6.02 Deficiency
	 	 	22	 
	ARTICLE VII MISCELLANEOUS
	 	 	22	 
	SECTION 7.01 Notices
	 	 	22	 
	SECTION 7.02 Cumulative Rights and No Waiver
	 	 	22	 
	SECTION 7.03 Applicable Law
	 	 	22	 

-i-

 

Table of Contents

(continued)

	 	 	 	 	 
	 	 	Page
	SECTION 7.04 Successor and Assigns
	 	 	23	 
	SECTION 7.05 Amendment
	 	 	23	 
	SECTION 7.06 Headings
	 	 	23	 
	SECTION 7.07 Severability
	 	 	23	 
	SECTION 7.08 Survivability
	 	 	23	 
	SECTION 7.09 Counterparts
	 	 	23	 
	SECTION 7.10 Dispute Resolution
	 	 	23	 
	SECTION 7.11 Enforcement Expenses; Indemnification
	 	 	23	 
	SECTION 7.12 Right of Set-Off
	 	 	24	 
	SECTION 7.13 Security Interest Absolute
	 	 	25	 
	SECTION 7.14 Termination or Release
	 	 	25	 
	SECTION 7.15 Collateral Agent Appointed Attorney-in-Fact
	 	 	25	 
	SECTION 7.16 General Authority of the Collateral Agent
	 	 	26	 
	SECTION 7.17 Reasonable Care
	 	 	27	 

-ii-

 

Exhibits

	 	 	 
	Exhibit A-1

	 	Form of Notice of Grant of Security Interest in Copyrights
	Exhibit A-2

	 	Form of Notice of Grant of Security Interest in Patents
	Exhibit A-3

	 	Form of Notice of Grant of Security Interest in Trademarks
	Exhibit B-1

	 	Form of Copyright Assignment
	Exhibit B-2

	 	Form of Trademark Assignment

Schedules

	 	 	 
	Schedule 1.02

	 	Material Agreements
	Schedule 3.01(b)

	 	Grantor Information
	Schedule 3.01(c)

	 	Filings
	Schedule 4.01(a)

	 	Intellectual Property Claims
	Schedule 4.01(b)

	 	Intellectual Property
	Schedule 4.01(c)

	 	Infringements
	Schedule 5.01(a)

	 	Pledged Collateral

-iii-

 

     SECURITY AGREEMENT dated as of July 31, 2008 among MSLO Emeril Acquisition Sub LLC, a Delaware
limited liability company (the “Borrower”), Martha Stewart Living Omnimedia, Inc., a
Delaware corporation (“Parent Guarantor” and, together with the Borrower, the
“Grantors”), and Bank of America, N.A., as collateral agent (in such capacity, together
with any successor collateral agent, the “Collateral Agent”) for the Secured Parties (as
defined below).

     Reference is made to the Loan Agreement dated as of April 4, 2008 (as amended, supplemented or
otherwise modified from time to time, the “Loan Agreement”), between the Borrower and Bank
of America, N.A. (together with any successor or assigns, the “Bank”). The Bank has agreed
to extend credit to the Borrower subject to the terms and conditions set forth in the Loan
Agreement. The obligations of the Bank to extend such credit are conditioned upon, among other
things, the execution and delivery of this Agreement. The Borrower is a wholly owned direct
Subsidiary of Parent Guarantor, who will derive substantial benefits from the extension of credit
to the Borrower pursuant to the Loan Agreement and Parent Guarantor is willing to execute and
deliver this Agreement in order to induce the Bank to extend such credit. Accordingly, the parties
hereto agree as follows:

ARTICLE I

DEFINITIONS

     SECTION 1.01 Loan Agreement. (a) Capitalized terms used in this Agreement and not otherwise defined herein have the
meanings specified in the Loan Agreement. All terms defined in the New York UCC (as defined
herein) and not defined in this Agreement have the meanings specified therein; the term
“instrument” shall have the meaning specified in Article 9 of the UCC. “UCC” means the New
York UCC; provided that, if perfection or the effect of perfection or non-perfection or the
priority of the security interest in any Collateral is governed by the Uniform Commercial Code as
in effect in a jurisdiction other than the State of New York, “UCC” means the Uniform
Commercial Code as in effect from time to time in such other jurisdiction for purposes of the
provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.

          (b) The rules of construction specified in Article I of the Loan Agreement also apply to this
Agreement.

     SECTION 1.02 Other Defined Terms. As used in this Agreement, the following terms have the meanings specified below:

     “Account Debtor” means any Person who is or who may become obligated to the Borrower
under, with respect to or on account of an Account.

     “Agreement” means this Security Agreement, as the same may be amended, amended and
restated, supplemented or otherwise modified from time to time.

     “Assignment” has the meaning assigned to such term in Section 4.08.

 

 

     “Bank” has the meaning assigned to such term in the preamble to this Agreement.

     “Bankruptcy Code” means Title 11 of the United States Code, as amended.

     “Books and Records” has the meaning assigned to such term in clause (xviii) of
Section 2.01(a).

     “Borrower” has the meaning assigned to such term in the preamble to this Agreement.

     “Business” means “Acquired Business,” as such term is defined in the Loan Agreement.

     “Cash Collateral Account” means the cash collateral account (account number ending in
1406537) opened by the Borrower with Bank of America, N.A. (and any substitute account therefor
maintained by the Borrower at the Collateral Agent).

     “Collateral” has the meaning assigned to such term in Section 2.01(a).

     “Collateral Agent” has the meaning assigned to such term in the preamble to this
Agreement.

     “Copyrights” has the meaning assigned to such term in the definition of “Intellectual
Property Collateral”.

     “Domain Names” has the meaning assigned to such term in the definition of
“Intellectual Property Collateral”.

     “Employment Agreements” means, collectively, (i) the Employment Agreement dated as of
April 2, 2008 between the Borrower (as assignee of Parent Guarantor) and Emeril J. Lagasse, III and
(ii) the Employment Agreement dated as of April 2, 2008 between the Borrower (as assignee of Parent
Guarantor) and Anthony Cruz, each as may be amended, amended and restated, supplemented or
otherwise modified from time to time.

     “Equity Interests” means, with respect to any Person, all of the shares, interests,
rights, participations or other equivalents (however designated) of capital stock of (or other
ownership or profit interests or units in) such Person and all of the warrants, options or other
rights for the purchase, acquisition or exchange from such Person of any of the foregoing
(including through convertible securities).

     “Escrow Agreement” means the Escrow Agreement dated as of April 2, 2008 among Emeril
J. Lagasse, III, Emeril’s Food of Love Productions, L.L.C. and emerils.com, LLC, the Borrower (as
assignee of Parent Guarantor), the SPE and the escrow agent named therein, as the same may be
amended, amended and restated, supplemented or otherwise modified from time to time.

2

 

     “Grantors” has the meaning assigned to such term in the preamble to this Agreement.

     “Guarantied Party” has the meaning assigned to such term in the Guaranty.

     “Guaranty” means the Continuing and Unconditional Guaranty dated as of April 4, 2008
made by each Guarantor in favor of the Collateral Agent, as the same may be, amended, amended and
restated, modified or supplemented from time to time.

     “Indemnitees” has the meaning assigned to such term in Section 7.11(b).

     “Intellectual Property” means, collectively, the Intellectual Property Collateral and
the SPE Intellectual Property.

     “Intellectual Property Collateral” means all of Borrower’s right, title and interest
in and to all intellectual property rights arising from or associated with the following, whether
protected, created or arising under the Laws of the United States or any other jurisdiction: (i)
trade names, trademarks and service marks (registered and unregistered), trade dress and similar
rights and applications to register any of the foregoing, and all goodwill associated therewith
(collectively, “Marks”); (ii) Internet domain names and other Internet addresses
(collectively, “Domain Names”); (iii) patents and patent applications and rights in respect
of utility models or industrial designs (collectively, “Patents”); (iv) copyrights and
registrations and applications therefore (collectively, “Copyrights”); (v) know-how, recipe
databases, inventions, discoveries, methods, processes, technical data, specifications, research
and development information, technology, data bases and other proprietary or confidential
information, in each case that derives economic value (actual or potential) from not being
generally know to other Persons who can obtain economic value from its disclosure, but excluding
any Copyrights or Patents that cover or protect any of the foregoing (collectively, “Trade
Secrets”); (vi) publicity rights and any other intellectual or industrial property rights of
any kind or nature that do not comprise Marks, Domain Names, Patents, Copyrights or Trade Secrets;
(vii) all license and distribution agreements, and covenants not to sue relating to any of the
foregoing; and (viii) all rights to sue for past, present or future infringement of any of the
foregoing.

     “Intellectual Property Security Agreement” means any of the short-form Notice of Grant
of Security Interest in Copyrights, Notice of Grant of Security Interest in Patents or Notice of
Grant of Security Interest in Trademarks, substantially in the form included in Exhibits A-1, A-2
and A-3, respectively, hereto.

     “Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement,
encumbrance, lien (statutory or other), charge, or preference, priority or other security interest
or preferential arrangement of any kind or nature whatsoever (including any conditional sale or
other title retention agreement, any easement, right of way or other encumbrance on title to real
property, and any capital lease having substantially the same economic effect as any of the
foregoing).

3

 

     “Loan Agreement” has the meaning assigned to such term in the preamble to this
Agreement.

     “Material Agreement” means any agreement set forth on Schedule 1.02 hereto, or any
other agreement to which a Grantor is a party relating to the Acquired Business, a breach under or
early termination of which could reasonably be expected to have a Material Adverse Effect.

     “New York UCC” means the Uniform Commercial Code as from time to time in effect in the
State of New York.

     “Parent Guarantor” has the meaning assigned to such term in the preamble to this
Agreement.

     “Parent Guarantor Collateral” has the meaning assigned to such term in Section
2.01(b).

     “Parent Guarantor Security Interest” has the meaning assigned to such term in Section
2.01(b).

     “Permitted Liens” has the meaning assigned to such term in Section 3.01(d).

     “Pledged Collateral” means, collectively, the Collateral described in clause (xv) of
Section 2.01(a) and clauses (i) through (iv) of Section 2.01(b).

     “Pledged Debt” means all debt securities owned by the Borrower and the promissory
notes and any other instruments evidencing such debt securities.

     “Pledged Equity” means all Equity Interests held by the Borrower and the certificates
representing such Equity Interests.

     “Pledged Securities” means any promissory notes, stock certificates or other
securities now or hereafter included in the Pledged Collateral, including all certificates,
instruments or other documents representing or evidencing any Pledged Collateral.

     “Publicity Rights License Agreement” means the Publicity Rights License Agreement
dated as of April 2, 2008 among Emeril J. Lagasse, III, the Borrower (as assignee of Parent
Guarantor) and the SPE, as the same may be amended, amended and restated, supplemented or otherwise
modified from time to time.

     “Purchase Agreement” means the Asset Purchase Agreement dated as of February 18, 2008
among Emeril J. Lagasse, III, Emeril’s Food of Love Productions, L.L.C. and emerils.com, LLC, as
sellers, and Parent Guarantor and the SPE, as purchasers, as the same may be amended, amended and
restated, supplemented or otherwise modified from time to time.

4

 

     “Secured Obligations” means, collectively, (i) the “Obligations” as defined in the
Loan Agreement, (ii) the “Guaranteed Obligations” as defined in the Guaranty and (iii) all
obligations and liabilities of the Grantors hereunder.

     “Secured Parties” means, collectively, the Bank, the Collateral Agent and all other
Guarantied Parties.

     “Security Interest” has the meaning assigned to such term in Section 2.01(a).

     “SPE Intellectual Property” means all of SPE’s right, title and interest in and to all
intellectual property rights arising from or associated with the following, whether protected,
created or arising under the Laws of the United States or any other jurisdiction: (i) Marks,
including that assigned by the Sellers to the SPE pursuant to the Purchase Agreement and set forth
on Schedule A to the SPE LLC Agreement; (ii) Domain Names; (iii) Patents; (iv) Copyrights; (v)
Trade Secrets; and (vi) publicity rights and any other intellectual or industrial property rights
of any kind or nature that do not comprise Marks, Domain Names, Patents, Copyrights or Trade
Secrets.

     “SPE” means MSLO Shared IP Sub LLC, a Delaware limited liability company.

     “Trade Secrets” has the meaning assigned to such term in the definition of
“Intellectual Property Collateral.”

ARTICLE II

SECURITY INTERESTS

     SECTION 2.01 Security Interest. (a) As security for the payment or performance, as the case may be, in full of the Secured
Obligations, including, without limitation, obligations under the Guaranty, the Borrower hereby
assigns and pledges to the Collateral Agent, its successors and assigns, for the benefit of the
Secured Parties, and hereby grants to the Collateral Agent, its successors and assigns, for the
benefit of the Secured Parties, a security interest (collectively, with the Parent Guarantor
Security Interest, the “Security Interest”) in, all right, title or interest in or to any
and all its assets and properties now owned or at any time hereafter acquired by the Borrower or in
which the Borrower now has or at any time in the future may acquire any right, title or interest,
including, without limitation, the following (collectively, with the Parent Guarantor Collateral,
the “Collateral”):

               (i) all Accounts;

               (ii) all Commercial Tort Claims;

               (iii) all Chattel Paper;

               (iv) all Documents;

5

 

               (v) all Equipment;

               (vi) all Fixtures, but only to the extent such Fixtures constitute personal property for
purposes of the UCC;

               (vii) all General Intangibles;

               (viii) all Goods;

               (ix) all Instruments;

               (x) all Intellectual Property Collateral (but excluding any United States intent-to-use
trademark application prior to the filing and acceptance of a statement of use or an amendment to
allege use in connection therewith to the extent that a valid security interest may not be taken on
such an intent-to-use trademark application under applicable Law);

               (xi) all Inventory;

               (xii) all Investment Property;

               (xiii) all Letters of Credit and Letter-of-Credit Rights;

               (xiv) all Money and all Deposit Accounts (including, without limitation, the Cash Collateral
Account);

               (xv) all Pledged Equity and Pledged Debt and all payments of principal or interest, dividends,
cash, instruments and other property from time to time received, receivable or otherwise
distributed in respect of, in exchange for or upon the conversion thereof;

               (xvi) all Supporting Obligations;

               (xvii) the Purchase Agreement, the Escrow Agreement, the Employment Agreements, the Publicity
Rights License Agreement and the other Transaction Documents, and the SPE Borrower License
Agreement;

               (xviii) all books and records pertaining to the Collateral including but not limited to any
computer-readable memory and any computer hardware or software necessary to process such memory
(“Books and Records”); and

               (xix) to the extent not otherwise included, all Proceeds and products of any and all of the
foregoing and all collateral security and guarantees given by any Person with respect to any of the
foregoing.

          (b) As security for the payment or performance, as the case may be, in full of the Secured
Obligations, including, without limitation, obligations under the Guaranty, Parent Guarantor hereby
assigns and pledges to the Collateral Agent,

6

 

its successors and assigns, for the benefit of the
Secured Parties, and hereby grants to the Collateral Agent, its successors and assigns, for the
benefit of the Secured Parties, a security interest (the “Parent Guarantor Security
Interest”) in, all right, title or interest in or to any and all of the following assets and
properties now owned or at any time hereafter acquired by Parent Guarantor or in which Parent
Guarantor now has or at any time in the future may acquire any right, title or interest
(collectively, the “Parent Guarantor Collateral”):

               (i) all of the Equity Interests of the Borrower;

               (ii) all additional Equity Interests issued by the Borrower acquired from time to time
acquired by Parent Guarantor in any manner;

               (iii) any certificates representing the shares referred to in clause (i) or (ii) above;

               (iv) all dividends, cash, interest, instruments and other property from time to time received
or otherwise distributed in respect of or in exchange for any or all of the foregoing;

               (v) the Purchase Agreement, the Escrow Agreement, the Employment Agreements, the Publicity
Rights License Agreement and the other Transaction Documents;

               (vi) all Contracts (as defined in the Purchase Agreement) to the extent such Contracts have
not been assigned to the Borrower;

               (vii) all Books and Records with respect to the Parent Guarantor Collateral; and

               (viii) to the extent not otherwise included, all Proceeds and products of any and all of the
foregoing and all collateral security and guarantees given by any Person with respect to any of the
foregoing.

     Notwithstanding anything in this Agreement to the contrary, any covenants made by the Parent
Guarantor under this Agreement with respect to any of its assets shall be limited to solely the
Parent Guarantor Security Interest and the Parent Guarantor Collateral.

          (c) Notwithstanding anything in this Agreement to the contrary, (i) “Collateral” shall not
include (A) any lease, license, contract or agreement to
which the relevant Grantor is a party, any of its rights or interests thereunder or any assets
subject thereto if the grant of such security interest shall constitute or result in (1) the
abandonment, invalidation or unenforceability of any right, title or interest of such Grantor
therein or result in any Grantor’s loss of use of such asset or (2) in a breach or termination
pursuant to the terms of, or a default under, any such lease, license, contract, or agreement
(other than to the extent that any such term would be rendered ineffective pursuant to
Sections 9-406, 9-407, 9-408 or
9-409 of the UCC (or any successor

7

 

provision or provisions) of any
relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of
equity); (B) any lease, license, contract or agreement to which the relevant Grantor is a party,
any of its rights or interests thereunder or any assets subject thereto to the extent that any
applicable law prohibits the creation of a security interest thereon (other than to the extent that
any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of
the UCC (or any successor provision or provisions) of any relevant jurisdiction or any other
applicable law (including the Bankruptcy Code) or principles of equity); or (C) any asset owned by
the relevant Grantor that is subject to a Lien described in Section 9.2(a)(ix) or (xi) of the Loan
Agreement if the contract or other agreement in such Lien is granted prohibits or requires the
consent of any Person other than a Loan Party and its Affiliates as a condition to the creation of
any other Lien on such asset; and (ii) any covenants made by the Parent Guarantor under this
Agreement with respect to any of its assets shall be limited to solely the Parent Guarantor
Security Interest and the Parent Guarantor Collateral.

          (d) Each Grantor hereby irrevocably authorizes the Collateral Agent for the benefit of the
Secured Parties at any time and from time to time to file in any relevant jurisdiction any initial
financing statements (including fixture filings) with respect to the Collateral or any part thereof
and amendments thereto that (i) with respect to the Borrower, indicate the Collateral as all assets
of such Grantor or words of similar effect as being of an equal or lesser scope or with greater
detail and (ii) contain the information required by Article 9 of the UCC or the analogous
legislation of each applicable jurisdiction for the filing of any financing statement or amendment,
including (A) whether such Grantor is an organization, the type of organization and any
organizational identification number issued to such Grantor and (B) in the case of a financing
statement filed as a fixture filing, a sufficient description of the real property to which such
Collateral relates. Each Grantor agrees to provide such information to the Collateral Agent
promptly upon request.

          (e) The Security Interest is granted as security only and shall not subject the Collateral
Agent or any other Secured Party to, or in any way alter or modify, any obligation or liability of
any Grantor with respect to or arising out of the Collateral.

ARTICLE III

REPRESENTATIONS WARRANTIES AND COVENANTS

     SECTION 3.01 General Representations and Warranties. Each Grantor jointly and severally represents and warrants to the Collateral Agent and the
Secured Parties that:

          (a) Each Grantor has good and valid rights in and title to the Collateral with respect to
which it has purported to grant a Security Interest hereunder and has full power and authority to
grant to the Collateral Agent the Security Interest in such Collateral pursuant hereto and to
execute, deliver and perform its obligations in

8

 

accordance with the terms of this Agreement,
without the consent or approval of any other Person other (i) than any consent or approval that has
been obtained and (ii) consents from the party (other than any Loan Party) to any contract or
agreement included in the Collateral necessary to make the Security Interest in such contract or
agreement enforceable against such party.

          (b) Each Grantor’s jurisdiction of organization, exact legal name, organizational
identification number, if any, and the location of such Grantor’s chief executive office or sole
place of business, in each case as of the date hereof, is specified on Schedule 3.01(b).

          (c) The Uniform Commercial Code financing statements (including fixture filings, as
applicable) or other appropriate filings, recordings or registrations prepared by the Collateral
Agent based upon such information for filing in each governmental, municipal or other office
specified in Schedule 3.01(c), including the Intellectual Property Security Agreements to be
executed and recorded in accordance with Section 4.06, are all the filings, recordings and
registrations that are necessary to establish a legal, valid and perfected security interest in
favor of the Collateral Agent (for the benefit of the Secured Parties) in respect of all Collateral
in which the Security Interest may be perfected by filing, recording or registration in the United
States (or any political subdivision thereof) and its territories and possessions, and no further
or subsequent filing, refiling, recording, rerecording, registration or reregistration is necessary
in any such jurisdiction, except as provided under applicable law with respect to the filing of
continuation statements.

          (d) The Security Interest constitutes (i) a legal and valid security interest in all the
Collateral securing the payment and performance of the Secured Obligations, (ii) subject to the
filings described in Section 3.01(c), a perfected security interest in all Collateral in which a
security interest may be perfected by filing, recording or registering a financing statement or
analogous document in the United States (or any political subdivision thereof) and its territories
and possessions pursuant to the UCC and (iii) a perfected security interest in all Intellectual
Property Collateral in which a security interest may be perfected upon the receipt and recording of
the applicable Intellectual Property Security Agreement with the United States Patent and Trademark
Office and the United States Copyright Office, as applicable, within the three-month period
(commencing as of the date hereof) pursuant to 35 U.S.C. § 261 or 15 U.S.C. § 1060 or the one month
period (commencing as of the date hereof) pursuant to 17 U.S.C. § 205. The Security Interest is
(to the extent such Security Interest can be perfected by filing) and shall be prior to any other
Lien on any of the Collateral, other than any
nonconsensual Lien that is expressly permitted pursuant to Section 9.2 of the Loan Agreement
and has priority as a matter of law (“Permitted Liens”).

     SECTION 3.02 Covenants. (a) No Grantor shall change its legal name, its type of organization, its status as a
registered organization (in the case of a registered organization), its jurisdiction of
organization, the location of its chief executive office or sole place of business, or its
organizational identification number (if any), except that any such changes shall be permitted (so
long as not in violation of the applicable

9

 

requirements of the Loan Documents and so long as same
do not involve (x) a registered organization ceasing to constitute the same or (y) any Grantor
changing its jurisdiction of organization or location to a jurisdiction of organization or
location, as the case may be, outside the United States or a State thereof) if (i) it shall have
given to the Collateral Agent not less than twenty (20) days’ prior written notice of such change,
and (ii) in connection with the respective such change or changes, it shall have taken all action
reasonably requested by the Collateral Agent to maintain the security interests of the Collateral
Agent in the Collateral intended to be granted hereby pursuant to this Agreement at all times fully
perfected and in full force and effect.

          (b) Each Grantor shall, at its own expense, maintain the security interest created by this
Agreement as a perfected security interest having at least the priority described in Section
3.01(d) and take any and all actions reasonably necessary to defend title to the Collateral against
all Persons and to defend the security interest of the Collateral Agent in the Collateral and the
priority thereof against any Lien that is not a Permitted Lien.

          (c) Each Grantor agrees, at its own expense, to execute, acknowledge, deliver and cause to be
duly filed all such further instruments and documents and take all such actions as the Collateral
Agent may from time to time reasonably request to better assure, preserve, protect and perfect the
Security Interest and the rights and remedies created hereby, including the payment of any fees and
taxes required in connection with the execution and delivery of this Agreement, the granting of the
Security Interest and the filing of any financing statements (including fixture filings) or other
documents in connection herewith or therewith.

          (d) At its option, the Collateral Agent may discharge past due taxes, assessments, charges,
fees, Liens, security interests or other encumbrances at any time levied or placed on the
Collateral that is not a Permitted Lien, and may pay for the maintenance and preservation of the
Collateral to the extent any Grantor fails to do so as required by the Loan Agreement or this
Agreement, and each Grantor jointly and severally agrees to reimburse the Collateral Agent within
five (5) days after written demand for any payment made or any reasonable expense incurred by the
Collateral Agent pursuant to the foregoing authorization. Nothing in this paragraph shall be
interpreted as excusing any Grantor from the performance of, or imposing any obligation on the
Collateral Agent or any Secured Party to cure or perform, any covenants or other promises of any
Grantor with respect to taxes, assessments, charges, fees, Liens, security
interests or other encumbrances and maintenance as set forth herein or in the other Loan
Documents.

          (e) If at any time any Grantor shall take a security interest in any property of an Account
Debtor or any other Person to secure payment and performance of an Account included in the
Collateral, such Grantor shall provide the Collateral Agent with prompt written notice thereof and,
upon the reasonable request of the Collateral Agent, shall promptly assign such security interest
to the Collateral Agent for the benefit of the Secured Parties. Such assignment need not be filed
of public record

10

 

unless necessary to continue the perfected status of the security interest against
creditors of and transferees from the Account Debtor or other Person granting the security
interest.

          (f) Each Grantor (rather than the Collateral Agent or any Secured Party) shall remain liable
(as between itself and any relevant counterparty) to observe and perform all the conditions and
obligations to be observed and performed by it under each contract, agreement or instrument
relating to the Collateral, all in accordance with the terms and conditions thereof, and each
Grantor jointly and severally agrees to indemnify and hold harmless the Collateral Agent and the
Secured Parties from and against any and all liability for such performance.

          (g) In the event that the proceeds of any insurance claim with respect to Collateral are paid
to any Grantor after the Collateral Agent has exercised its right to foreclose in accordance with
the terms of this Agreement, such proceeds shall be held in trust for the benefit of the Collateral
Agent and immediately after receipt thereof shall be paid to the Collateral Agent for application
in accordance with the Loan Agreement.

          (h) No Grantor shall amend, modify or waive any provision of any Material Agreement in a
manner that (i) could reasonably be expected to be materially adverse to the interests of the
Collateral Agent and the Secured Parties or (ii) materially reduces or delays the payments to be
made to the Grantor thereunder, in each case, without the Collateral Agent’s prior written consent
(which consent shall not be unreasonably conditioned, withheld or delayed).

     SECTION 3.03 Other Actions. In order to further insure the attachment, perfection and priority of, and the ability of
the Collateral Agent to enforce, the Security Interest, each Grantor represents and warrants as
follows and agrees, in each case at such Grantor’s own expense, to take the following actions with
respect to the following Collateral:

          (a) Instruments and Tangible Chattel Paper. As of the date hereof, no amounts payable under
or in connection with any of the Collateral are evidenced by any Instrument or Tangible Chattel
Paper. If at any time any amount then payable under or in connection with any of the Collateral
shall be evidenced by any Instrument or Tangible Chattel Paper having a face value in excess of
$25,000, the Grantor acquiring such Instrument or Tangible Chattel Paper shall promptly (but in any
event within ten (10) days after receipt thereof) endorse, assign and deliver the same to the
Collateral Agent, accompanied by such instruments of transfer or assignment duly executed in blank
as the Collateral Agent may from time to time specify.

          (b) Deposit Accounts. The Borrower shall not establish or maintain any Deposit Account,
except with Bank of America, N.A. while it is the Collateral Agent or, if Bank of America, N.A. is
not the Collateral Agent, any other bank (as defined in Section 9-102 of the UCC) whose
jurisdiction (determined in accordance with Section 9-304 of the UCC) is within a State of the
United States with the Collateral Agent’s prior written consent. The Borrower agrees that it shall
not grant “control”

11

 

within the meaning of Section 9-104 of the UCC of any Collateral comprised of
Deposit Accounts to any Person other than the Collateral Agent.

          (c) Investment Property. If any Grantor shall at any time hold or acquire any certificated
securities constituting Collateral, such Grantor shall promptly endorse, assign and deliver the
same to the Collateral Agent for the benefit of the Secured Parties, accompanied by such
instruments of transfer or assignment duly executed in blank as the Collateral Agent may from time
to time reasonably request. If any securities now or hereafter acquired by any Grantor and
constituting Collateral are uncertificated and are issued to such Grantor or its nominee directly
by the issuer thereof, such Grantor shall either (i) cause the issuer to agree to comply with
instructions from the Collateral Agent as to such securities, without further consent of any
Grantor or such nominee, or (ii) arrange for the Collateral Agent to become the registered owner of
the securities. If any securities, whether certificated or uncertificated, or other investment
property are held by any Grantor or its nominee through a securities intermediary or commodity
intermediary, such Grantor shall, pursuant to an agreement in form and substance reasonably
satisfactory to the Collateral Agent, either (i) cause such securities intermediary or (as the case
may be) commodity intermediary to agree to comply with entitlement orders or other instructions
from the Collateral Agent to such securities intermediary as to such security entitlements, or (as
the case may be) to apply any value distributed on account of any commodity contract as directed by
the Collateral Agent to such commodity intermediary, in each case without further consent of any
Grantor or such nominee, or (ii) in the case of financial assets or other Investment Property held
through a securities intermediary, arrange for the Collateral Agent to become the entitlement
holder with respect to such Investment Property, with the Grantor being permitted, only with the
consent of the Collateral Agent, to exercise rights to withdraw or otherwise deal with such
Investment Property. The provisions of this paragraph shall not apply to any financial assets
credited to a securities account for which the Collateral Agent is the securities intermediary.
Each Grantor agrees that it shall not grant “control” within the meaning of Section 9-106 of the
UCC of any Collateral comprised of Securities Accounts or Securities Entitlements to any Person
other than the Collateral Agent.

          (d) Letter-of-Credit Rights. If any Grantor is at any time a beneficiary under a Letter of
Credit having a face value in excess of $25,000 now or hereafter issued in respect of Collateral,
such Grantor shall promptly notify the Collateral Agent thereof and such Grantor shall, at the
request of the Collateral Agent, either (i)
arrange for the issuer and any confirmer of such Letter of Credit to consent to an assignment
to the Collateral Agent of the proceeds of any drawing under the Letter of Credit or (ii) arrange
for the Collateral Agent to become the transferee beneficiary of such Letter of Credit, in each
case, pursuant to an agreement in form and substance reasonably satisfactory to the Collateral
Agent.

          (e) Commercial Tort Claims. As of the date hereof, the Borrower hereby represents and
warrants that it holds no Commercial Tort Claims. If the Borrower shall at any time hold or
acquire a Commercial Tort Claim, it shall promptly (and in any event within ten (10) days) notify
the Collateral Agent in writing signed by

12

 

the Borrower of the details thereof and grant to the
Collateral Agent in such writing a security interest therein and in the Proceeds thereof, all upon
the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory
to the Collateral Agent.

ARTICLE IV

CERTAIN PROVISIONS CONCERNING INTELLECTUAL PROPERTY

     SECTION 4.01 Representations and Warranties. Each of Parent Guarantor and Borrower jointly and severally represents and warrants to the
Collateral Agent and the Secured Parties that:

        (a) The Borrower or the SPE owns, free and clear of all Liens other than Permitted Liens, or
is otherwise licensed to use, all intellectual property used in or necessary for the conduct of the
Business as currently conducted, all of which rights shall survive unchanged upon the consummation
of the transactions contemplated by this Agreement. Except as set forth in Schedule 4.01(a), no
legal proceedings are pending or, to the knowledge of such Grantor, threatened, in which any Person
is challenging the use of any Intellectual Property or the validity or effectiveness of any
Intellectual Property, nor does such Grantor know of any valid basis for any such claim.

        (b) Except pursuant to the licenses entered into by the Borrower or the SPE (or their
predecessors-in-interest) that are listed in Schedule 4.01(b), on and as of the date hereof (i)
each of the Borrower and the SPE owns, and has done nothing to authorize or enable any other person
to use, any Intellectual Property that is owned or purported to be owned by the Borrower or the
SPE, as the case may be. Schedule 4.01(b) sets forth a true and complete list of all registered
Intellectual Property, in each case owned or filed by the Borrower or the SPE, and all such
registrations and applications for registration listed are subsisting, and, to the knowledge of
such Grantor, valid.

        (c) Except as set forth on Schedule 4.01(c), to the knowledge of such Grantor, on and as of
the date hereof, (i) there is no material violation by any other Person of any Intellectual
Property owned by the Borrower or the SPE, (ii) neither the Borrower nor the SPE is infringing upon
any intellectual property rights of any other Person, and (iii) no proceedings have been instituted
or are pending against the Borrower
or the SPE or threatened, and no claim against Borrower or SPE has been received by Borrower
or SPE, alleging any such violation.

     SECTION 4.02 Grant of License. For the purpose of enabling the Collateral Agent, upon the occurrence and during the
continuance of an Event of Default, to exercise rights and remedies under Article VI hereof at such
time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies, and
for no other purpose, the Borrower hereby grants to the Collateral Agent an irrevocable,
non-exclusive license, exercisable only after an Event of Default has occurred and is continuing
and without payment of royalty or other compensation to the Borrower, to use, license or sublicense
any of the Intellectual Property Collateral, or assign any of the Intellectual

13

 

Property Collateral
now owned or hereafter acquired by the Borrower, wherever the same may be located, including in
such license access to all media in which any of the licensed items may be recorded or stored and
to all computer programs used for the compilation or printout hereof, in each case, subject to the
applicable provisions of Article VI hereof and Part 6 of Article 9 of the New York UCC.

     SECTION 4.03 Protection of Collateral Agent’s Security. On a continuing basis, the Borrower shall, at its sole cost and expense, (i) within thirty
(30) days of its becoming aware thereof, notify the Collateral Agent of (A) any adverse final
determination in any proceeding in the United States Patent and Trademark Office or the United
States Copyright Office with respect to any Mark, Copyright or Patent included in the Intellectual
Property that is material to the Business, or (B) the institution of any proceeding or any adverse
determination in any federal, state or local court or administrative body regarding the Borrower’s
or the SPE’s claim of ownership in or right to use any of the Intellectual Property that is
material to the Business, its right to register such Intellectual Property or its right to keep and
maintain such registration in full force and effect, (ii) maintain and protect, and cause the SPE
to maintain and protect, the Intellectual Property material to the Business, (iii) not permit to
lapse or become abandoned any Intellectual Property material to the Business as presently used and
operated and as contemplated, and not settle or compromise any pending or future litigation or
administrative proceeding with respect to such Intellectual Property, in each case except as shall
be consistent with commercially reasonable business judgment, (iv) within thirty (30) days of the
Borrower obtaining knowledge thereof, notify the Collateral Agent in writing of any event which
would reasonably expected to materially and adversely affect the value or utility of the
Intellectual Property or any portion thereof material to the use and operation of the Business, the
ability of the Borrower or the Collateral Agent to dispose of the Intellectual Property Collateral
or any portion thereof or the rights and remedies of the Collateral Agent in relation thereto
including, without limitation, by means of a levy or threat of levy or any legal process against
the Intellectual Property or any portion thereof, (v) not, without the prior consent of the
Collateral Agent (which consent shall not be unreasonably withheld, delayed or conditioned), (A)
license the Intellectual Property Collateral (including any sublicense under the SPE Borrower
License Agreement) other than pursuant to the Trademark License Agreement and
licenses entered into by the Borrower in, or incidental to, the ordinary course of business,
on arms’ length terms, or (B) amend or permit the amendment of any of the licenses in a manner that
materially and adversely affects the right to receive payments thereunder, or in any manner that
would materially impair the value of the Intellectual Property or the Lien on and security interest
in the Intellectual Property Collateral intended to be granted to the Collateral Agent for the
benefit of the Secured Parties, (vi) diligently keep adequate records respecting the Intellectual
Property and (vii) furnish to the Collateral Agent from time to time upon the Collateral Agent’s
reasonable request therefor detailed statements and amended schedules further identifying and
describing the Intellectual Property and such other materials evidencing or reports pertaining to
the Intellectual Property as the Collateral Agent may from time to time reasonably request.

     SECTION 4.04 Modifications. Borrower authorizes the Collateral Agent to modify this Agreement by amending Schedule
4.01(b) to include any Intellectual Property

14

 

Collateral acquired or arising after the date hereof
of Borrower including, without limitation, any of the items listed in Section 4.07.

     SECTION 4.05 Litigation. Unless any Event of Default shall have occurred and be continuing, Borrower and the SPE
shall have the right to commence and prosecute in their own names, as the party in interest, for
their own benefit and at their sole cost and expense, such applications for protection of the
Intellectual Property and suits, proceedings or other actions to prevent the infringement,
counterfeiting, unfair competition, dilution, diminution in value or other damage as are necessary
to protect the Intellectual Property. Upon the occurrence and during the continuance of any Event
of Default, the Collateral Agent shall have the right but shall in no way be obligated to file
applications for protection of the Intellectual Property in the name of Borrower or the SPE, as
applicable, and/or bring suit in the name of Borrower, the SPE (subject to the rights granted to
Emeril’s Food of Love Productions, L.L.C. and the Emeril Lagasse Foundation pursuant to Section
4.05 of the Trademark License Agreement and to the applicable terms of the SPE Borrower License
Agreement) the Collateral Agent or the Secured Parties to enforce the Intellectual Property and any
license thereunder (subject to the applicable terms of the SPE Borrower License Agreement). In the
event of such suit, Borrower shall, or shall cause the SPE to, at the reasonable request of the
Collateral Agent, do any and all lawful acts and execute any and all documents requested by the
Collateral Agent in aid of such enforcement and Borrower shall promptly reimburse and indemnify the
Collateral Agent, as the case may be, for all reasonable costs and expenses incurred by the
Collateral Agent in the exercise of its rights under this Section 4.05. In the event that the
Collateral Agent shall elect not to bring suit to enforce the Intellectual Property upon the
occurrence and during the continuance of any Event of Default, Borrower agrees, at the reasonable
request of the Collateral Agent, to, or shall cause the SPE to, take all commercially reasonable
actions necessary, whether by suit, proceeding or other action, to prevent the infringement,
counterfeiting, unfair competition, dilution, diminution in value of or other damage to any of the
Intellectual Property by others and for that
purpose agrees to diligently maintain any suit, proceeding or other action against any person
so infringing necessary to prevent such infringement.

     SECTION 4.06 Intellectual Property Security Agreements. With respect to the registered Copyrights, applications to register Copyrights, Marks,
applications to register Marks and Patents included in the Intellectual Property Collateral,
Borrower agrees to execute a Copyright Grant, a Patent Grant and a Trademark Grant in the forms
attached hereto as Exhibits A-1, A-2 and A-3, for recording the security interest granted hereunder
in such Intellectual Property Collateral with the United States Patent and Trademark Office and the
United States Copyright Office and Borrower agrees to execute any other document reasonably
requested by the Collateral Agent for recording with any other Governmental Authority necessary to
perfect the security interest granted hereunder in such Intellectual Property Collateral.

     SECTION 4.07 After-Acquired Property. If Borrower shall, at any time before the Secured Obligations have been paid in full,
(i) obtain any rights to any additional Intellectual Property or (ii) become entitled to the
benefit of any additional Intellectual Property or any renewal or extension thereof, including any
reissue, division, continuation, or

15

 

continuation-in-part of any Intellectual Property, or any
improvement on any Intellectual Property, the provisions hereof shall automatically apply thereto
and any such item enumerated in clause (i) or (ii) of this Section 4.07 with respect to Borrower
shall automatically constitute Intellectual Property Collateral if such would have constituted
Intellectual Property Collateral at the time of execution hereof and be subject to the Lien and
security interest created by this Agreement without further action by any party. Borrower shall
within thirty (30) days of acquiring an item of Intellectual Property enumerated in clause (i) or
(ii) of this Section 4.07, provide to the Collateral Agent with written notice of any of the
foregoing and (ii) if Borrower, confirm the attachment of the Lien and security interest created by
this Agreement to any rights described in clauses (i) and (ii) of the immediately preceding
sentence of this Section 4.07 by execution of an instrument in form reasonably acceptable to the
Collateral Agent. If the SPE, at any time before the Secured Obligations have been paid in full,
shall file with the United States Patent and Trademark Office an application to register any Mark
or if any registration of a Mark is granted by the United States Patent and Trademark Office to the
SPE, the Borrower will use commercially reasonable efforts to provide written notice to the
Collateral Agent of such filing or registration within thirty (30) days thereafter.

     SECTION 4.08 Assignments. Borrower has delivered to the Collateral Agent a copyright assignment and trademark
assignment with respect to the Copyrights and Marks included in the Intellectual Property
Collateral in the form attached to this Agreement as Exhibits B-1 and B-2 (collectively, the
“Assignment”), which Assignment shall be held by the Collateral Agent and shall not be
effective until the Collateral Agent has foreclosed upon
the Copyrights and/or Marks included in the Collateral in accordance with the terms of this
Agreement and applicable law. In connection with the Collateral Agent’s exercise of its rights and
remedies with respect to Intellectual Property Collateral and subject to applicable law, if any
Event of Default has occurred and is continuing, upon the foreclosure upon and sale of the
Collateral (or the acceptance of Intellectual Property Collateral by the Secured Parties in full or
partial satisfaction of the Secured Obligations) the Collateral Agent may complete the Assignment,
update Schedule 1 thereto to set forth a complete list of the Copyrights and Marks included
in the Collateral and file or cause to be filed such completed Assignment with the United States
Copyright Office or the United States Patent and Trademark Office, as applicable, to evidence the
applicable sale or assignment of the Intellectual Property Collateral.

     SECTION 4.09 Power of Attorney. Borrower hereby grants to the Collateral Agent an absolute power of attorney to sign, upon
the occurrence and during the continuance of an Event of Default, any document which may be
required by the United States Patent and Trademark Office, United States Copyright Office or any
other Governmental Authority in order to effect an absolute assignment of all right, title and
interest in or to any Intellectual Property Collateral, and record the same.

16

 

ARTICLE V

CERTAIN PROVISIONS CONCERNING PLEDGED COLLATERAL

     SECTION 5.01 Representations and Warranties. Each Grantor jointly and severally represents and warrants to the Collateral Agent and the
Secured Parties that:

          (a) As of the date hereof, Schedule 5.01(a) correctly sets forth the percentage of the issued
and outstanding units of each class of the Equity Interests of the issuer thereof represented by
the Pledged Equity and includes all Equity Interests, debt securities and promissory notes required
to be pledged hereunder.

          (b) The Pledged Equity and Pledged Debt have been duly and validly authorized and issued by
the issuers thereof and (i) in the case of Pledged Equity, are fully paid and nonassessable and
(ii) in the case of Pledged Debt, are, to the knowledge of such Grantor, legal, valid and binding
obligations of the issuers thereof (except as may be limited by the application of bankruptcy,
insolvency and other laws affecting creditors’ rights generally and by application of principles of
equity, regardless of whether considered in an action or proceeding brought in equity or at law).

          (c) Except for restrictions and limitations imposed by the Loan Documents or applicable law
generally, the Pledged Collateral is and will continue to be freely transferable and assignable,
and none of the Pledged Collateral is or will be subject to any option, right of first refusal,
shareholders agreement, charter or by-law provisions or contractual restriction of any nature that
might prohibit, impair, delay or otherwise
affect in any manner material and adverse to the Secured Parties the pledge of such Pledged
Collateral hereunder, the sale or disposition thereof pursuant hereto or the exercise by the
Collateral Agent of rights and remedies hereunder;

          (d) each of the Grantors has the power and authority to pledge the Pledged Collateral pledged
by it hereunder in the manner hereby done or contemplated;

          (e) no consent or approval of any Governmental Authority, any securities exchange or any other
Person was or is necessary to the validity of the pledge effected hereby (other than such as have
been obtained and are in full force and effect);

          (f) by virtue of the execution and delivery by the Grantors of this Agreement, when any
Pledged Securities are delivered to the Collateral Agent in accordance with this Agreement, the
Collateral Agent will obtain a legal, valid and perfected lien upon and security interest in such
Pledged Securities as security for the payment and performance of the Secured Obligations; and

          (g) the pledge effected hereby is effective to vest in the Collateral Agent, for the benefit
of the Secured Parties, the rights of the Collateral Agent in the Pledged Collateral as set forth
herein.

17

 

     SECTION 5.02 Delivery of the Pledged Collateral. (a) Each Grantor agrees promptly to deliver or cause to be delivered to the Collateral
Agent, for the benefit of the Secured Parties, any and all Pledged Securities (other than any
uncertificated securities, but only for so long as such securities remain uncertificated).
(b) Upon delivery to the Collateral Agent, (i) any Pledged Securities shall be accompanied by
stock powers duly executed in blank or other instruments of transfer reasonably satisfactory to the
Collateral Agent and by such other instruments and documents as the Collateral Agent may reasonably
request and (ii) all other property comprising part of the Pledged Collateral shall be accompanied
by proper instruments of assignment duly executed by the applicable Grantor and such other
instruments or documents as the Collateral Agent may reasonably request.

     SECTION 5.03 Certification of Limited Liability Company and Limited Partnership
Interests. Each interest in any limited liability company or limited partnership that is represented
by a certificate controlled by any Grantor and pledged under Section 2.01 shall be a “security”
within the meaning of Article 8 of the New York UCC and shall be governed by Article 8 of the New
York UCC.

     SECTION 5.04 Registration in Nominee Name; Denominations. If an Event of Default shall occur and be continuing, (a) the Collateral Agent, on behalf
of the Secured Parties, shall have the right (in its sole and absolute discretion) to hold the
Pledged Securities in its own name as pledgee, the name of its nominee (as pledgee or as sub-agent)
or the name of the applicable Grantor, endorsed or assigned in blank or in favor of the Collateral
Agent and each Grantor will promptly give to the Collateral Agent copies of any notices or other
communications received by it with respect to Pledged Securities registered in the name of such
Grantor and (b) the Collateral Agent shall have the right to exchange the certificates representing
Pledged Securities for certificates of smaller or larger denominations for any purpose consistent
with this Agreement.

     SECTION 5.05 Voting Rights; Dividends and Interest. (a) Unless and until an Event of Default shall have occurred and be continuing:

               (i) Each Grantor shall be entitled to exercise any and all voting and/or other consensual
rights and powers inuring to an owner of Pledged Securities or any part thereof for any purpose not
inconsistent with the terms of this Agreement, the Loan Agreement and the other Loan Documents.

               (ii) The Collateral Agent shall execute and deliver to each Grantor, or cause to be executed
and delivered to such Grantor, all such proxies, powers of attorney and other instruments as any
Grantor may reasonably request for the purpose of enabling such Grantor to exercise the voting
and/or consensual rights and powers it is entitled to exercise pursuant to paragraph (i) above.

               (iii) Each Grantor shall be entitled to receive and retain any and all dividends, interest,
principal and other distributions paid on or distributed in respect of the Pledged Securities to
the extent and only to the extent that such dividends, interest, principal and other distributions
are permitted by, and otherwise paid or

18

 

distributed in accordance with, the terms and conditions of
the Loan Agreement, the other Loan Documents and applicable law; provided that any noncash
dividends, interest, principal or other distributions that would constitute Pledged Equity or
Pledged Debt, whether resulting from a subdivision, combination or reclassification of the
outstanding Equity Interests of the issuer of any Pledged Securities or received in exchange for
Pledged Securities or any part thereof, or in redemption thereof, or as a result of any merger,
consolidation, acquisition or other exchange of assets to which such issuer may be a party or
otherwise, shall be and become part of the Pledged Collateral, and, if received by any Grantor,
shall be held in trust for the benefit of the Collateral Agent and the Secured Parties and shall be
promptly delivered to the Collateral Agent in the same form as so received (with any necessary
endorsement reasonably requested by the Collateral Agent). So long as no Default or Event of
Default has occurred and is continuing, the Collateral Agent agrees that it will cooperate with the
applicable Grantor to promptly deliver any Pledged Securities in its possession to the issuer of
such Pledged Securities in connection with any exchange or redemption of such Pledged Securities
pursuant to arrangements reasonably satisfactory to the Collateral Agent intended to
maintain the Collateral Agent’s perfected lien in such Pledged Securities and any
consideration received in exchange therefor or in redemption thereof.

          (b) Upon the occurrence of and during the continuance of an Event of Default, all rights of
any Grantor to dividends, interest, principal or other distributions that such Grantor is
authorized to receive pursuant to paragraph (a)(iii) of this Section 5.05 shall cease, and all such
rights shall thereupon become vested in the Collateral Agent, which shall have the sole and
exclusive right and authority to receive and retain such dividends, interest, principal or other
distributions. All dividends, interest, principal or other distributions received by any Grantor
contrary to the provisions of this Section 5.05 shall be held in trust for the benefit of the
Collateral Agent, and shall be promptly delivered to the Collateral Agent upon demand in the same
form as so received (with any necessary endorsement reasonably requested by the Collateral Agent).
Any and all money and other property paid over to or received by the Collateral Agent pursuant to
the provisions of this paragraph (b) shall be retained by the Collateral Agent in a cash collateral
account upon receipt of such money or other property and shall be applied in accordance with the
Loan Documents.

          (c) Upon the occurrence and during the continuance of an Event of Default, then all rights of
any Grantor to exercise the voting and consensual rights and powers it is entitled to exercise
pursuant to paragraph (a)(i) of this Section 5.05, and the obligations of the Collateral Agent
under paragraph (a)(ii) of this Section 5.05, shall cease, and all such rights shall thereupon
become vested in the Collateral Agent, which shall have the sole and exclusive right and authority
to exercise such voting and consensual rights and powers.

19

 

ARTICLE VI

REMEDIES

     SECTION 6.01 Remedies Upon Default. If an Event of Default shall occur and be continuing, it is agreed that the Collateral
Agent shall have the right to exercise any and all rights afforded to a secured party with respect
to the Secured Obligations under the UCC or other applicable law and also may (i) require each
Grantor to, and each Grantor agrees that it will at its expense and upon request of the Collateral
Agent promptly, assemble all or part of the Collateral as directed by the Collateral Agent and make
it available to the Collateral Agent at a place and time to be designated by the Collateral Agent
that is reasonably convenient to both parties; (ii) occupy any premises owned or, to the extent
lawful and permitted, leased by any of the Grantors where the Collateral or any part thereof is
assembled or located for a reasonable period in order to effectuate its rights and remedies
hereunder or under law, without obligation to such Grantor in respect of such occupation;
provided that the Collateral Agent shall provide the applicable Grantor with notice thereof
prior to or promptly after such occupancy (but the failure of the Collateral Agent to provide such
notice shall not limit the Collateral Agent’s rights with respect thereto); (iii) exercise any and
all rights and remedies of any of the Grantors under or in
connection with the Collateral, or otherwise in respect of the Collateral; provided
that the Collateral Agent shall provide the applicable Grantor with notice thereof prior to or
promptly after such exercise (but the failure of the Collateral Agent to provide such notice shall
not limit the Collateral Agent’s rights with respect thereto); and (iv) subject to the mandatory
requirements of applicable Law and the notice requirements described below, sell or otherwise
dispose of all or any part of the Collateral securing the Secured Obligations at a public or
private sale or at any broker’s board or on any securities exchange, for cash, upon credit or for
future delivery as the Collateral Agent shall deem appropriate. The Collateral Agent shall be
authorized at any such sale of securities (if it deems it advisable to do so) to restrict the
prospective bidders or purchasers to Persons who will represent and agree that they are purchasing
the Collateral for their own account for investment and not with a view to the distribution or sale
thereof, and upon consummation of any such sale the Collateral Agent shall have the right to
assign, transfer and deliver to the purchaser or purchasers thereof the Collateral so sold. Each
such purchaser at any sale of Collateral shall hold the property sold absolutely, free from any
claim or right on the part of any Grantor, and each Grantor hereby waives (to the extent permitted
by law) all rights of redemption, stay and appraisal which such Grantor now has or may at any time
in the future have under any rule of law or statute now existing or hereafter enacted.
Notwithstanding the foregoing, unless and until a “Statement of Use” or an “Amendment to Allege
Use” has been filed and accepted in the United States Patent and Trademark Office, it is agreed
that the Collateral Agent’s right to assign, transfer or convey any Collateral consisting of Marks
for which an application is pending under Section 1(b) of the Lanham Act, 15 U.S.C. § 1051(b), or
any of its successors or counterparts, shall only be exercised if any such assignment, transfer or
conveyance occurs in connection with the transfer of the business (or the portion of the business)
to which such Collateral consisting of Marks pertains and is made to the successor of that
business.

20

 

     The Collateral Agent shall give the applicable Grantors ten (10) days’ written notice (which
each Grantor agrees is reasonable notice within the meaning of Section 9-611 of the New York UCC or
its equivalent in other jurisdictions) of the Collateral Agent’s intention to make any sale of
Collateral. Such notice, in the case of a public sale, shall state the time and place for such
sale and, in the case of a sale at a broker’s board or on a securities exchange, shall state the
board or exchange at which such sale is to be made and the day on which the Collateral, or portion
thereof, will first be offered for sale at such board or exchange. Any such public sale shall be
held at such time or times within ordinary business hours and at such place or places as the
Collateral Agent may fix and state in the notice (if any) of such sale. At any such sale, the
Collateral, or portion thereof, to be sold may be sold in one lot as an entirety or in separate
parcels, as the Collateral Agent may (in its sole and absolute discretion) determine. The
Collateral Agent shall not be obligated to make any sale of any Collateral if it shall determine
not to do so, regardless of the fact that notice of sale of such Collateral shall have been given.
The Collateral Agent may, without notice or publication, adjourn any public or private sale or
cause the same to be adjourned from time to time by announcement at the time and place fixed for
sale, and such sale may, without further notice, be made at the time and place to which the same
was so adjourned. In case any sale of all or any part of the Collateral is made on credit or for
future delivery, the Collateral so sold may be retained by the Collateral Agent until the sale
price is paid by the purchaser or purchasers thereof, but the Collateral Agent shall not incur any
liability in case any such purchaser or purchasers shall fail to take up and pay for the Collateral
so sold and, in case of any such failure, such Collateral may be sold again upon like notice. At
any public (or, to the extent permitted by applicable law, private) sale made pursuant to this
Agreement, any Secured Party may bid for or purchase, free (to the extent permitted by law) from
any right of redemption, stay, valuation or appraisal on the part of any Grantor (all said rights
being also hereby waived and released to the extent permitted by applicable law), the Collateral or
any part thereof offered for sale and may make payment on account thereof by using any claim then
due and payable to such Secured Party from any Grantor as a credit against the purchase price, and
such Secured Party may, upon compliance with the terms of sale, hold, retain and dispose of such
property without further accountability to any Grantor therefor. For purposes hereof, a written
agreement to purchase the Collateral or any portion thereof shall be treated as a sale thereof; the
Collateral Agent shall be free to carry out such sale pursuant to such agreement and no Grantor
shall be entitled to the return of the Collateral or any portion thereof subject thereto,
notwithstanding the fact that after the Collateral Agent shall have entered into such an agreement
all Events of Default shall have been remedied and the Secured Obligations paid in full. As an
alternative to exercising the power of sale herein conferred upon it, the Collateral Agent may
proceed by a suit or suits at law or in equity to foreclose this Agreement and to sell the
Collateral or any portion thereof pursuant to a judgment or decree of a court or courts having
competent jurisdiction or pursuant to a proceeding by a court-appointed receiver. Any sale
pursuant to the provisions of this Section 6.01 shall be deemed to conform to the commercially
reasonable standards as provided in Section 9-610(b) of the New York UCC or its equivalent in other
jurisdictions.

21

 

     Each Grantor irrevocably makes, constitutes and appoints the Collateral Agent (and all
officers, employees or agents designated by the Collateral Agent) as such Grantor’s true and lawful
agent (and attorney-in-fact) for the purpose of (i) making, settling and adjusting claims in
respect of Collateral under policies of insurance, endorsing the name of such Grantor on any check,
draft, instrument or other item of payment for the proceeds of such policies of insurance, (ii)
making all determinations and decisions with respect thereto and (iii) obtaining or maintaining the
policies of insurance required by Section 7.10 of the Loan Agreement or to pay any premium in whole
or in part relating thereto, in each case only upon the occurrence and during the continuance of an
Event of Default. All sums disbursed by the Collateral Agent in connection with this paragraph,
including reasonable attorneys’ fees, court costs, expenses and other charges relating thereto,
shall be payable, within five (5) days of written demand therefor, by the Grantors to the
Collateral Agent and shall be additional Secured Obligations secured hereby.

     SECTION 6.02 Deficiency. Each Grantor shall remain liable for any deficiency if the proceeds of any sale of other
disposition of the Collateral are insufficient to pay the Secured Obligations and the fees
and expenses of any Person employed by the Collateral Agent or any other Secured Party to collect
such deficiency in accordance with Section 7.11.

ARTICLE VII

MISCELLANEOUS

     SECTION 7.01 Notices. All notices and other communications hereunder shall (except as otherwise expressly
permitted herein) be in writing and given as provided in Section 12 of the Loan Agreement or
Section 18 of the Guaranty.

     SECTION 7.02 Cumulative Rights and No Waiver. Each and every right granted to the Collateral Agent and the Secured Parties under any Loan
Document, or allowed it by law or equity shall be cumulative of each other and may be exercised in
addition to any and all other rights of the Collateral Agent or the Secured Parties, and no delay
in exercising any right shall operate as a waiver thereof, nor shall any single or partial exercise
by the Collateral Agent or the Secured Parties of any right preclude any other or future exercise
thereof or the exercise of any other right. Each Grantor expressly waives any presentment, demand,
protest or other notice of any kind, including but not limited to notice of intent to accelerate
and notice of acceleration, except in the event and to the extent that any such notice is expressly
required by the terms of any Loan Document. No notice to or demand on any Grantor in any case
shall, of itself, entitle such Grantor to any other or future notice or demand in similar or other
circumstances.

     SECTION 7.03 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York. To the extent that the Collateral Agent or any Secured Party has greater rights or
remedies under federal law, whether as a national bank or otherwise, this paragraph shall not be
deemed to deprive such Person of such rights and remedies as may be available under federal law.

22

 

     SECTION 7.04 Successor and Assigns. This Agreement is binding on each Grantor and its successors and assignees and shall inure
to the benefit of the Collateral Agent and each other Secured Party and their successors and
assigns; provided that no Grantor may assign any of its rights or obligations under this
Agreement without the Collateral Agent’s prior written consent (and any purported assignment in
violation of this Section 7.04 shall be null and void).

     SECTION 7.05 Amendment. No modification, consent, amendment or waiver of any provision of this Agreement, nor consent to
any departure by any Grantor therefrom, shall be effective unless the same shall be in writing and
signed by the Collateral Agent and each Grantor.

     SECTION 7.06 Headings. Section and paragraph headings are for reference only and shall not affect the
interpretation or meaning of any provisions of this Agreement.

     SECTION 7.07 Severability. If any part of this Agreement is not enforceable, the rest of the Agreement may be
enforced.

     SECTION 7.08 Survivability. All covenants, agreements, representations and warranties made by any Grantor herein or in
the other Loan Documents to which such Grantor is a party shall survive the making of the Loan and
shall continue in full force and effect so long as the Secured Obligations, or any portion thereof,
are outstanding.

     SECTION 7.09 Counterparts. This Agreement may be executed in as many counterparts as necessary or convenient, and by
the different parties on separate counterparts each of which, when so executed, shall be deemed an
original but all such counterparts shall constitute but one and the same agreement. Signatures may
be delivered via telecopy or in PDF format via electronic mail and signatures delivered by such
means shall be deemed originals for all purposes.

     SECTION 7.10 Dispute Resolution. The Dispute Resolution Provision as set forth under Section 13.13 of the Loan Agreement
shall apply. By agreeing to binding arbitration, the parties irrevocably and voluntarily waive any
right they may have to a trial by jury in respect of any Claim. Furthermore, without intending in
any way to limit this Agreement to arbitrate, to the extent any Claim is not arbitrated, the
parties irrevocably and voluntarily waive any right they may have to a trial by jury in respect of
such Claim. This waiver of jury trial shall remain in effect even if the Class Action Waiver is
limited, voided or found unenforceable. WHETHER THE CLAIM IS DECIDED BY ARBITRATION OR BY TRIAL BY
A JUDGE, THE PARTIES AGREE AND UNDERSTAND THAT THE EFFECT OF THIS AGREEMENT IS THAT THEY ARE GIVING
UP THE RIGHT TO TRIAL BY JURY TO THE EXTENT PERMITTED BY LAW.

     SECTION 7.11 Enforcement Expenses; Indemnification. (a) Each Grantor, jointly and severally, agrees to pay or reimburse (i) all costs and
reasonable attorney’s

23

 

fees incurred by the Collateral Agent and the Secured Parties in connection
with the enforcement, collection or protection of its rights in connection with this Agreement and
the other Loan Documents to which such Grantor is party, including its rights under this Section
and (ii) all reasonable costs and expenses incurred by the Collateral Agent in the administration
of this Agreement and the other Loan Documents to which such Grantor is a party. As used in this
paragraph, “attorneys’ fees” includes the allocated costs of in-house counsel. In addition, each
Grantor agrees to, upon reasonable notice from the Collateral Agent, pay any and all stamp and
other taxes or fees payable or determined to be payable in connection with the execution and
delivery of this Agreement and the other documents to be delivered hereunder, and agrees to save
the Collateral Agent harmless from and against any and all liabilities with respect to or resulting
from any delay in paying or omission to pay such taxes or fees.

          (b) Each Grantor, jointly and severally, agrees to indemnify and hold the Collateral Agent and
the other Secured Parties and their parent entities, Subsidiaries and all of their directors,
officers, employees, agents, successors, attorneys, and assigns (collectively, the
“Indemnitees”), harmless from any loss, liability, damages, judgments, and costs of any
kind relating to or arising directly or indirectly out of (a) this Agreement or any other Loan
Document, the Security Interest or the Collateral and (b) any litigation or proceeding related to
or arising out of this Agreement, any such document, the Security Interest or the Collateral, in
each case other than arising as a result of any such Indemnitee’s gross negligence or willful
misconduct. This indemnity includes but is not limited to reasonable attorneys’ fees (including
the allocated cost of in-house counsel). Under no circumstances shall any of the Indemnitees have
any liability for any special, punitive, indirect or consequential damages relating to this
Agreement or any other Loan Document or arising out of its activities in connection herewith or
therewith.

          (c) Any such amounts payable as provided hereunder shall be additional Secured Obligations
secured hereby. The provisions of this Section 7.11 shall remain operative and in full force and
effect regardless of the termination of this Agreement or any other Loan Document, the consummation
of the transactions contemplated hereby, the repayment of any of the Secured Obligations, the
invalidity or unenforceability of any term or provision of this Agreement or any other Loan
Document, or any investigation made by or on behalf of the Collateral Agent or any other Secured
Party. All amounts due under this Section 7.11 shall be payable upon demand.

     SECTION 7.12 Right of Set-Off. In addition to any rights and remedies of the Secured Parties provided by applicable law,
upon the occurrence and during the continuance of any Event of Default, each Secured Party is
authorized at any time and from time to time, without prior notice to any Grantor, any such notice
being waived by each Grantor to the fullest extent permitted by applicable law, to set off and
apply any and all deposits (general or special, time or demand, provisional or final) at any time
held by, and other
indebtedness at any time owing by, such Secured Party to or for the credit or the account of
the respective Loan Parties and their Subsidiaries against any and all Secured Obligations owing to
such Secured Party hereunder or under any other Loan Document, now or hereafter existing,
irrespective of whether or not such Secured Party

24

 

or Affiliate shall have made demand under this
Agreement or any other Loan Document and although such obligations may be contingent or unmatured
or denominated in a currency different from that of the applicable deposit or indebtedness. Each
Secured Party agrees promptly to notify Parent Guarantor and the Collateral Agent in writing after
any such set off and application made by such Secured Party; provided that the failure to
give such notice shall not affect the validity of such setoff and application. The rights of the
Collateral Agent and each Secured Party under this Section 7.12 are in addition to other rights and
remedies (including other rights of setoff) that the Collateral Agent and such Secured Party may
have.

     SECTION 7.13 Security Interest Absolute. All rights of the Collateral Agent hereunder, the Security Interest and all obligations of
each Grantor hereunder shall be absolute and unconditional irrespective of (a) any lack of validity
or enforceability of the Loan Agreement, any other Loan Document, any agreement with respect to any
of the Secured Obligations or any other agreement or instrument relating to any of the foregoing,
(b) any increase in, or any change in the time, manner or place of payment of, or in any other term
of, all or any of the Secured Obligations, or any other amendment or waiver of or any consent to
any departure from the Loan Agreement, any other Loan Document or any other agreement or
instrument, (c) any exchange, release or non-perfection of any Lien on other collateral, or any
release or amendment or waiver of or consent under or departure from any guarantee, securing or
guaranteeing all or any of the Secured Obligations or (d) subject to the terms of Section 7.14, any
other circumstance that might otherwise constitute a defense available to, or a discharge of, any
Grantor in respect of the Secured Obligations or this Agreement.

     SECTION 7.14 Termination or Release. (a) This Agreement and the Security Interest shall terminate with respect to all Secured
Obligations when all the outstanding Secured Obligations have been indefeasibly paid in full and
the Secured Parties have no further commitment under the Loan Agreement or other agreements
evidencing the Secured Obligations.

          (b) Upon the effectiveness of any written consent to the release of the security interest
granted hereby in any Collateral pursuant to Section 13.6 of the Loan Agreement, the security
interest in such Collateral shall be automatically released.

          (c) In connection with any termination or release pursuant to paragraph (a) or (b) above, the
Collateral Agent shall execute and deliver to any Grantor, at such Grantor’s expense, all documents
that such Grantor shall reasonably request to
evidence such termination or release. Any execution and delivery of documents pursuant to
this Section 7.14 shall be without recourse to or warranty by the Collateral Agent.

     SECTION 7.15 Collateral Agent Appointed Attorney-in-Fact. Each Grantor hereby appoints the Collateral Agent the attorney-in-fact of such Grantor for
the purpose of carrying out the provisions of this Agreement and taking any action and executing
any instrument that the Collateral Agent may deem necessary or advisable to accomplish the purposes
hereof at any time after an Event of Default has occurred and is continuing, which appointment is
irrevocable and coupled with an interest. Without

25

 

limiting the generality of the foregoing, the
Collateral Agent shall have the right, upon the occurrence and during the continuation of an Event
of Default, with full power of substitution either in the Collateral Agent’s name or in the name of
such Grantor (a) to receive, endorse, assign and/or deliver any and all notes, acceptances, checks,
drafts, money orders or other evidences of payment relating to the Collateral or any part thereof;
(b) to demand, collect, receive payment of, give receipt for and give discharges and releases of
all or any of the Collateral; (c) to sign the name of any Grantor on any invoice or bill of lading
relating to any of the Collateral; (d) to send verifications of Accounts Receivable to any Account
Debtor; (e) to commence and prosecute any and all suits, actions or proceedings at law or in equity
in any court of competent jurisdiction to collect or otherwise realize on all or any of the
Collateral or to enforce any rights in respect of any Collateral; (f) to settle, compromise,
compound, adjust or defend any actions, suits or proceedings relating to all or any of the
Collateral; (g) to notify, or to require any Grantor to notify, Account Debtors to make payment
directly to the Collateral Agent; and (h) to use, sell, assign, transfer, pledge, make any
agreement with respect to or otherwise deal with all or any of the Collateral, and to do all other
acts and things necessary to carry out the purposes of this Agreement, as fully and completely as
though the Collateral Agent were the absolute owner of the Collateral for all purposes;
provided that nothing herein contained shall be construed as requiring or obligating the
Collateral Agent to make any commitment or to make any inquiry as to the nature or sufficiency of
any payment received by the Collateral Agent, or to present or file any claim or notice, or to take
any action with respect to the Collateral or any part thereof or the moneys due or to become due in
respect thereof or any property covered thereby. The Collateral Agent and the other Secured
Parties shall be accountable only for amounts actually received as a result of the exercise of the
powers granted to them herein, and neither they nor their officers, directors, employees or agents
shall be responsible to any Grantor for any act or failure to act hereunder, except for their own
gross negligence or willful misconduct or that of any of their Affiliates, directors, officers,
employees, counsel, agents or attorneys-in-fact.

     SECTION 7.16 General Authority of the Collateral Agent. By acceptance of the benefits of this Agreement and any other Loan Documents, each Secured
Party (whether or not a signatory hereto) shall be deemed irrevocably (a) to consent to the
appointment of the Collateral Agent as its agent hereunder and under such other Loan Documents, (b)
to confirm that the Collateral Agent shall have the authority to act as the exclusive agent of such
Secured Party for the
enforcement of any provisions of this Agreement and such other Loan Documents against any
Grantor, the exercise of remedies hereunder or thereunder and the giving or withholding of any
consent or approval hereunder or thereunder relating to any Collateral or any Grantor’s obligations
with respect thereto, (c) to agree that it shall not take any action to enforce any provisions of
this Agreement or any other Loan Document against any Grantor, to exercise any remedy hereunder or
thereunder or to give any consents or approvals hereunder or thereunder except as expressly
provided in this Agreement or any other Loan Document and (d) to agree to be bound by the terms of
this Agreement and any other Loan Documents. The Collateral Agent may resign at any time by giving
written notice thereof to the Secured Parties and the Borrower. Upon any such resignation, the
Bank shall appoint a successor Collateral Agent who shall be willing to accept, and accepts, such
appointment within thirty (30) days after the retiring Collateral Agent shall have given notice of
resignation

26

 

(such appointment to be subject to the prior written approval of the Borrower, which
approval may not be unreasonably withheld or delayed and shall not be required upon the occurrence
and during the continuance of an Event of Default). Upon the acceptance of such appointment by the
successor Collateral Agent, such successor Collateral Agent shall succeed to and become vested with
all the rights, powers and privileges and duties of the retiring Collateral Agent, and the retiring
Collateral Agent shall be discharged from its duties and obligations under this Agreement and the
other Loan Documents (but shall continue to have the benefit of Sections 7.10, 7.11 and 7.17
hereof).

     SECTION 7.17 Reasonable Care. The Collateral Agent is required to exercise reasonable care in the custody and
preservation of any of the Collateral in its possession; provided, that the Collateral
Agent shall be deemed to have exercised reasonable care in the custody and preservation of any of
the Collateral if such Collateral is accorded treatment substantially similar to that which the
Collateral Agent accords its own property, it being understood that neither the Collateral Agent
nor any of the Secured Parties shall have responsibility for (i) ascertaining or taking action with
respect to calls, conversions, exchanges, maturities, tenders or other matters relating to any
Investment Property, whether or not the Collateral Agent or any other Secured Party has or is
deemed to have knowledge of such matters, or (ii) taking any necessary steps to preserve rights
against any Person with respect to any Collateral.

[This space left intentionally blank.]

27

 

     IN WITNESS WHEREOF, the parties hereto have caused this Security Agreement to be duly
executed as of the date first above written.

	 	 	 	 	 
	 	MARTHA STEWART LIVING OMNIMEDIA, INC.

 	 
	 	By:  	/s/
Howard Hochhauser	 
	 	 	Name:  	Howard Hochhauser	 
	 	 	Title:  	Chief Financial Officer	 
	 

	 	 	 	 	 
	 	MSLO EMERIL ACQUISITION SUB LLC

 	 
	 	By:  	/s/
Howard Hochhauser	 
	 	 	Name:  	Howard Hochhauser	 
	 	 	Title:  	Vice President	 
	 

	 	 	 	 	 
	 	BANK OF AMERICA, N.A.

as Collateral Agent

 	 
	 	By:  	/s/
Jane Heller	 
	 	 	Name:  	Jane Heller	 
	 	 	Title:  	Senior Vice President	 
	 

[Signature page to Security Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]